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Abstract
The pathogenesis of chronic obstructive pulmonary disease (COPD) is known to be closely linked
to cigarette smoke exposure, or to be more precise, to the abnormal inflammatory response
caused by inhalation of cigarette smoke or, rarely, of other inhalative noxes. The effects of
cigarette smoke most often include the development of emphysema and chronic bronchitis
leading to decline in lung function and subsequently to the loss of life quality and life time.
Chronic inflammation, which plays a major role in the development of COPD can mainly be
attributed to progressive activation of immune cells, which increases with exposure time. It
was also shown that immune function changes with age, sometimes leading to overreactions.
These changes on the one hand lead to the increase of autoimmune diseases, on the other hand
they also predispose to immunodeficiencies. But even now, the immune system and especially
its changes with age are still not fully understood.
Since increased inflammatory response plays an important role in the development of COPD,
we hypothesized that in a mouse model for the development of COPD by chronic cigarette
smoke exposure, the pathogenesis of COPD is characterized by an elevated immune response in
aged mice compared to young animals.
To proof our hypothesis, female C57BL/6 mice aged 2 and 12 months were exposed to cigarette
smoke with a concentration of 500 mg/m3, using a smoking chamber to create full body exposure
and mimic human smoking habits. Exposure was performed twice a day for 50 min for three
months. Control animals were handled, but only exposed to filtered air. Differential cell counts
and inflammatory cell recruitment were performed using FACS on bronchoalveolar lavage and
homogenates of whole lung tissue respectively. Other parameters for disease progression that
were considered were lung function and emphysema development (by use of a stereological tool).
We have found a decline in lung function due to cigarette smoke in old animals after 3 months
of cigarette smoke exposure (demonstrated by an increase in lung compliance), while there
were still no changes in lung function of the younger animals. Further analysis also showed an
enlargement of alveolar space and an increase in airway collagen in old cigarette smoke exposed
mice, that could not be found in the younger animals. Furthermore, we discovered an increase in
tertiary lymphoid structures (iBALT) in the lung tissue of old cigarette smoke exposed animals
only, which led to our hypothesis, that the changes in lung structure and function occured due
to immunoageing. Therefore, we analysed different cell lines to find changes due to cigarette
smoke exposure and age. Differential cell counts of BAL cytospins revealed significantly higher
lymphocyte levels in aged animals, whereas comparable increases in macrophage and neutrophil
numbers for all CS-exposed mice were observed. In old animals, we found an increase in Th17
positive T-helper cells due to cigarette smoke exposure. An increase in the amount of these
cells has been described to show a strong correlation with decline of lung function. Additionally,
staining for MMP12 in lung tissue revealed significantly higher macrophage accumulation and
activation in CS-exposed aged mice, which was in accordance with increased MMP12 mRNA
expression and an elevated MMP12/TIMP1 ratio.
COPD-like changes in the lungs of mice were only observed in the lungs of the older animals
at this timepoint. Correspondingly macrophage levels as well as Th17 cell levels were only
increased in the older cigarette smoke exposed animals. This leads us to the conclusion, that
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the difference in lung damage due to cigarette smoke exposure in old vs. young animals can
indeed be explained by differences in the immune reaction.
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Zusammenfassung
Es ist bekannt, dass das Auftreten der chronisch obstruktiven Lungenerkrankung (COPD) eng
mit dem Zigarettenrauchen verknüpft ist. Um genauer zu sein, ist es zurückzuführen auf die
abnormale Immunantwort auf den Zigarettenrauch, oder selten auch auf andere inhalatorische
Noxen. Die Folgen von Zigarettenrauchen sind unter anderem die Entwicklung von Lungenem-
physem und chronischer Bronchitis, die zu einer Verschlechterung der Lungenfunktion und
damit zu einem Verlust von Lebensqualität und Lebenszeit führen. Die chronische Entzündung,
die eine der Hauptrollen in der Entwicklung der COPD spielt, ist vor allem der progressiven
Aktivierung von Immunzellen zuzuschreiben. Diese steigt mit der Expositionszeit. Es wurde
bereits gezeigt, dass das Immunsystem sich im Alter verändert, und teilweise überreagiert. Ein
Beispiel hierfür ist das häufigere Auftreten von Autoimmunerkrankungen im Alter. Andererseits
prädisponiert ein höheres Alter auch für Immundefekte. Allerdings sind das Immunsystem und
vor allem seine Veränderungen mit dem ALter noch immer nicht gänzlich erforscht.
Da eine gesteigerte Immunantwort eine wichtige Rolle in der Entwicklung der COPD spielt,
haben wir angenommen, dass in einem Mausmodell die Exposition mit Zigarettenrauch zu
der Entwicklung einer COPD führt. Die Pathogenese der COPD sollte durch eine gesteigerte
Immunantwort der älteren Tiere im Vergleich mit den Jüngeren charakterisiert sein.
Um unsere Hypothese zu prüfen haben wir weibliche C57BL/6 Mäuse im Alter von 2 und 12
Monaten Zigarettenrauch mit einer Konzentration von 500 mg/m3 ausgesetzt. Hierfür haben
wir eine Rauchkammer benutzt, um eine Exposition des ganzen Körpers der Mäuse zu erre-
ichen und damit menschliches Rauchverhalten möglichst genau abzubilden. Die Exposition
wurde 3 Monate lang, zweimal täglich für je 50 min durchgeführt. Die Kontrolltiere wurden
umgesetzt, aber nur gefilterter Luft ausgesetzt. Differenzierte Zellzählungen und die Analyse
von Entzündungszellen wurde mittels eines FACS-Geräts an der bronchoalveolaren Lavage
und dem homogenisierten Lungengewebe durchgeführt. Die anderen Parameter, die für die
Analyse des Fortschreitens der Erkrankung herangezogen wurden, waren die Bestimmung von
Lungenfunktion und die Emphysementwicklung (diese wurde mit Hilfe eines stereologischen
Werkzeugs bestimmt).
Nach 3-monatiger Exposition fanden wir eine Verschlechterung der Lungenfunktion durch Zi-
garettenrauch bei den älteren Tieren nach 3 Monaten Exposition (was sich durch einen Anstieg
der Lungencompliance zeigte), während sich bei den jungen Tieren noch keine Veränderungen
zeigten. Weitere Untersuchungen zeigten eine Vergrößerung der Alveolarräume, sowie die Ver-
mehrung von Collagen in den Wänden der Atemwege. Diese Veränderungen ließen sich bei den
jüngeren Tieren nicht nachweisen. Zudem fanden wir eine Vermehrung von tertiären lymphoiden
Strukturen (iBALT), die sich nur im Lungengewebe der älteren berauchten Mäuse nachweisen
lässt. Dies führte uns zu der Hypothese, dass die Veränderungen von Lungenstruktur und
-funktion durch die altersbedingten Veränderungen des Immunsystems bedingt sind. Daher über-
prüften wir verschiedene Zelllinien auf durch Alter und Zigarettenrauch bedingte Unterschiede.
Differenzierte Zellzählungen aus der BAL zeigten signifikant erhöhte Lymphozyten-Level bei
den älteren Tieren, während die Vermehrung von Makrophagen und Neutrophilen in allen
berauchten Gruppen zu finden war. Bei den älteren Tieren fanden wir einen durch Zigaret-
tenrauch verursachten Anstieg der Th17 positiven T-Helfer Zellen. Eine Vermehrung dieser
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Zellen zeigte eine starke Korrelation mit einer Verschlechterung der Lungenfunktion. Die
immunohistochemische Färbung des Lungengewebes mit einem MMP12-Antikörper zeigte eine
erhöhte Rekrutierung und Aktivierung von Makrophagen bei berauchten Mäusen. Dies zeigte
sich auch in einer erhöhten MMP12-mRNA Expression und einem erhöhten MMP12/TIMP1
Verhältnis.
COPD-typische Veränderungen zeigten sich zum Untersuchungszeitpunkt nur in den Lungen der
berauchten älteren Mäuse. Damit übereinstimmend fanden wir nur bei den älteren berauchten
Mäusen eine Vermehrung von Makrophagen und Th17-Zellen. Dies führt uns zu dem Schluss,
dass die unterschiedlichen Ausmaße der Lungenschädigung durch Exposition mit Zigaretten-
rauch bei älteren und jüngeren Mäusen durchaus durch Unterschiede in der Immunreaktion
erklärt werden können.
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1 Introduction
1.1 Chronic obstructive pulmonary disease (COPD)
1.1.1 Definition and diagnosis of COPD
COPD is a disease that is defined by three main pathological characteristics: the limitation of
airflow, the development of emphysema and the chronic inflammation of airways [1].
For the clinical diagnosis of COPD, the most important parameter is airflow limitation. For
clinical diagnosis a forced expiratory volume (the maximum volume the patient can exhale
in one second = FEV1) of less than 70% of the vital capacity of the patient is sufficient to
diagnose COPD. The severity of the disease is further characterized by FEV1 of the patient
compared to a healthy reference group adjusted to gender, height and weight according to the
classification of the GOLD stages (see table 1) [2].
The treatment of COPD requires inter alia the reduction of exacerbations. Exacerbations
GOLD stage Severity of air flow limitation
GOLD 1 mild FEV1 ≥ 80% of reference value
GOLD 2 moderate 50% ≤ FEV1 < 80% of reference value
GOLD 3 severe 30% ≤ FEV1 < 50% of reference value
GOLD 4 very severe FEV1 < 30% of reference value
Table 1: Characterisation of disease stage according to air flow limitation as described in [2].
are defined as “acute events characterized by a worsening of a patient’s respiratory symptoms
that is beyond normal day-to-day variation and leads to a change in medication”[2]. The
likelyhood of exacerbations is a factor to be regarded in the assignment to therapeutic groups.
The patient’s risk group is determined by the amount of exacerbations and their lung function
classification. Patients characterized as low risk have a lung function that classifies them as
GOLD stages 1 or 2 and ≤ 1 exacerbations per year. These exacerbations must not require
hospitalisation. Patients characterized as high risk have a lung function classifying as GOLD
stages 3 or 4 and have ≥ 2 exacerbations per year. In addition, one exacerbation that requires
hospitalisation nessesarily classifies the patients into the high risk group.
Another parameter that defines the line of therapy is the amount of symptoms. For the
classification of symptoms there are two scales: The mMRC-scale (see table 2) and the COPD-
Assessment-Test-scale (the CAT questionnaire can be taken from [3]). Patients reaching 0-1
points on the mMRC scale or <10 points on the CAT scale are classified as less symptomatic
patients. Patients reaching ≥ 2 points on mMRC or ≥ 10 points on the CAT scale are classified
as more symptomatic.
According to these parameters, patients are distributed into different treatment groups as seen
in figure 1.
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Grade Symptoms
Grade 1 Patient’s breath is as good as the healthy reference group
Grade 2 Patient has difficulties climbing hills or stairs
Grade 3 Patient is able to walk at his own speed for about a mile or more
Grade 4 Patient is able to walk more than about 100 yards on the level.
Grade 5 Patient is unable to leave his house or breathless while talking
Table 2: mMRC-scale according to [4]
Figure 1: Combined Assessment of COPD according to GOLD [2]
1.1.2 Epidemiology of COPD
According to WHO reports [5], COPD has been found to be the fourth leading cause of death
worldwide. It is estimated to be the third leading cause of death by 2030. This makes the
analysis of risk factors and pathomechanisms a very important task for the future of medical
treatments. Even though other risk factors for the development of COPD have been described,
cigarette smoking is still the most important one in developed countries. Lundbäck et al. [6]
have conducted a study showing a significant increase in COPD cases for cigarette smokers
compared to non-smokers. They have also revealed an age dependent increase in the prevalence
of COPD in both, the smoking group and the non smoking group. The percentages of patients
with COPD in the study, depending on age and smoking habits are given in table 3. The
amount of ex-smokers diagnosed with COPD has been shown to range between that of smokers
and non-smokers.
Ageing additionally seems to be a predisposing factor for the development of COPD. This
Age Non-Smokers Smokers
46-47 1% 5%
61-62 2% 24%
76-77 16% 45%
Table 3: Table of COPD prevalence in % depending on age group and smoking habits, generated with the data presented
in [6]
has been shown in epidemiological analyses by an age dependent increase in the percentage of
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Figure 2: COPD prevalence according to age group and gender [7], M= male , W=female, T= total
patients diagnosed with COPD. An increase with ageing has also been found in the severity
of the disease, as defined by the GOLD stages (see figure 2) [7]. Even though lung function
physiologically declines during the process of ageing, there are significant differences between
smokers and non smokers in the development of COPD.
COPD is a very serious lung disease, as the patients suffer from a significant impairment to
their everyday lives. It has been shown that patients suffering from COPD have a significantly
decreased 6 minute walking distance compared to subjects not suffering that disease. It has
also been determined that COPD patients have a lower Barthel-index, which is an indicator of
how much a person is able to cope in their everyday life and care for themselves [8].
However, patients with COPD do not only suffer from a significant loss of life quality, but also
of lifetime. Feenstra et al. have discovered that male COPD patients lose an average of 8 years
off their lifetime, while female COPD patients lose a total of 10.5 years off their life expectancy
compared to people without a COPD diagnosis [9].
1.1.3 Pathology of COPD
1.1.3.1 Small airway remodelling
Small airway wall thickness has been reported to have a strong correlation with FEV1, which is
the most relevant clinical parameter for the diagnosis of COPD. FEV1 defines the stages 1-4 in
the GOLD classification. It has been shown, that increasing severity of clinical symptoms and
advancing stages, correlate with an increase in the thickness of small airways [1]. A correlation
has also been found between small airway wall area percentage and clinical severity of the
disease. Another parameter that closely correlates with disease severity is the “percentage of
occlusion of the fully expanded airway lumen by inflammatory exudates containing mucus”[10].
Using this correlation, one could also classify the inner luminal area of small airways as a
parameter closely correlated to FEV1. These correlations have been proven both by histological
analysis of lung tissue from patients and in measurements taken from computertomographic
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(CT) images [10],[11].
In addition to the increase of airway thickness with the progression of the disease, it has also
been demonstrated that in COPD patients the amount of micro vessels in the walls of small
airways is significantly increased compared to the healthy control group [12].
1.1.3.2 Emphysema development
Emphysema is one of the foremost terms that comes to mind when talking about COPD.
However, only a weak correlation between lung function analysis, in particular FEV1, and
emphysema exists. This is not surprising, as FEV1 is determined by the airway area. None
the less, emphysema development severely reduces the diffusion capacity of the lung, as it
reduces the alveolar surface area. Emphysema is classically determined by pathological methods.
Radiologic methods such as CT have taken over the diagnostic process in most cases. There
has been proven to be a good correlation between CT analysis values for emphysema and
pathological analysis [13].
It has been found that emphysematous lesions can be induced by intratracheal instillation of
human elastase into animal lungs [14]. These findings lead to the assumption, that emphysema
in humans can be caused by an imbalance of elastases and anti-elastases in the lung. This
theory is supported by the fact, that humans with α1 -antitrypsin deficiency develop emphysema
independent of cigarette smoke exposure. But even without this genetic defect smokers develop
emphysema. In the analysis of bronchoalveolar lavage fluid from smokers, a chronic increase in
elastase levels as well as in MMP-levels (matrix-metalle-proteinases) could be found. Additionally
an acute increase in neutrophil elastase activity following cigarette smoke exposure has been
found [15]. In addition to the increase in elastase levels a decrease in the levels of anti-protease
activation could be found in patients with COPD [16]. But even in healthy smokers the activity
of α1 antitrypsin is reduced in comparison to non smokers. This is suggested to be caused by the
inactivation of α1 -antitrypsin by methionine sulfoxide [17]. An analysis of emphysema severity
(analysed by CT imaging) and the comparison to elastase and antielastase levels in BAL have
shown a direct correlation between elastase levels and emphysema severity. Anti-elastase levels
on the other hand have shown an indirect correlation to the severity of the disease [18].
Interestingly women have been found to be more susceptible to cigarette smoke induced COPD,
especially in the early stages of COPD. The latter has been demonstrated by a greater lung
function reduction as well as a more severe disease compared to men after exposure to the same
amount of cigarette smoke [19]. In contrast to those findings a greater emphysema development
in men compared to women at the same stage of COPD has been discovered [20].
1.1.3.3 Chronic bronchitis and tertiary lymphoid structures
COPD has been known to cause not only airflow limitation, but also chronic inflammation of
the airways. Chronic bronchitis usually manifests in chronic coughing as well as in increased
sputum production. In patients with chronic bronchitis pulmonary biopsies have shown an
increased number of total leukocytes in comparison to healthy control subjects. This increase is
mostly due to an increase in macrophages and T-lymphocytes [21]. In patients that additionally
suffer from airflow limitation, an increase in macrophages could be detected that was significant
even compared to patients suffering from chronic bronchitis only . It has been found that the
amount of inflammatory cells such as CD8 positive T-cells, neutrophilic and eosinophilic cells
show a positive correlation with the clinical severity of COPD [22].
The inflammatory cells in airways have been found to mostly be organized in lymphoid follicles
14
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[1]. These so called iBALT (inducible Bronchus Associated Lymphoid tissue) structures have
been described to consist of B-cell follicles as well as T-cell areas. iBALT structures seem
to support B-and T-cell proliferation [23]. Inflammation of airways has been described to
persist in patients with COPD even after one year of smoking cessation. In smokers that were
asymptomatic before smoking cessation however, inflammation of the airways decreases [24].
1.1.3.4 Pulmonary hypertension
Pulmonary arterial hypertension is a common complication in patients with COPD especially
in patients of stages III and IV according to GOLD. It has been unveiled that 36% of these
patients develop pulmonary hypertension. Pulmonary hypertension in COPD patients is also
associated with a lower survival rate [25].
In patients with pulmonary hypertension alterations in arterial structure have been found in
comparison to control groups. Analysis of medium and larger muscular arteries have shown
increased percentages of media and intima compared to the healthy control groups. Additionally
a trend towards an increase in muscle in the media of smaller arteries has been detected [26].
Furthermore, IL 6 seems to play a role in the development of pulmonary hypertension as a
correlation between IL 6 levels and the degree of pulmonary hypertension has been found
[27]. Even though there does not seem to be a correlation between pulmonary hypertension
and either lung function or emphysema development, a correlation between the increase in
pulmonary blood pressure and a decrease in PaO2 has been found. Patients with pulmonary
hypertension also seem to suffer from more severe dyspnoea compared to patients with the
same or even more airway obstruction with normal pulmonary blood pressure [27], [28].
It has been suggested that long term oxygen therapy in patients with severe COPD and
pulmonary hypertension may decrease pulmonary arterial blood pressure, even though the
values do not return to baseline levels [29].
1.1.4 Therapeutic approaches to COPD
The treatment of COPD patients is given according to the needs of the patient. The patients
are distributed into groups ranging from A to D defined by GOLD [2] as described in chapter
1.1.1. An overview over the treatment options for COPD was described in [30]. The guidelines
for treatment of COPD given by GOLD is presented in figure 3.
1.1.4.1 Smoking cessation
It has been known for a long time, that smoking is the main risk factor for the development of
chronic obstructive pulmonary disease. It accounts for appoximately 80% of all COPD related
deaths [31]. Therefore, prevention of disease development and exacerbations by terminating
exposure to the main risk factor is an essential element in the therapeutic approach. It has
been shown that after smoking cessation, lung function in COPD patients declines at a much
slower rate, similar to the physiological age dependent decline, than in the patients that
continue smoking [32], [33]. The rates of lung funtion decline in smokers and non-smokers are
demonstrated in figure 4.
Smoking cessation has also been shown to reduce airway reactivity which leads to an increase
in FEV1, which has been found to be the primary marker for lung function in COPD [35].
15
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Figure 3: Treatment guidelines according to GOLD [2]
Figure 4: Lung function decline due to ageing and cigarette smoke. According to figure 1 in [33], taken from [34]
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Figure 5: Mechanisms of bronchodialation (picture taken from [39]
1.1.4.2 β2-agonists
One of the approaches to symptomatic treatment of COPD is bronchodialation. There are two
main kinds of bronchodialators that are used in the standard therapy according to the GOLD
guidelines for COPD treatment. The most commonly used group is β2 agonists that can be
further divided into the groups of short acting and long acting β2 agonists (see table 4).
Short acting β2 agonists have been shown to significantly increase both FEV1 as well as FVC
(forced vital capacity) in patients with COPD [36]. Studies have shown that under therapy with
short acting β2 agonists long acting β2 agonists
Salbutamol Formoterol
Fenoterol Salmeterol
Terbutalin Indacaterol (ultra long acting)
Reproterol
Albuterol
Table 4: List of β2 -agonists
long acting β2 agonists symptoms in COPD patients decrease by a greater amount than with
the use of short acting β2 agonists [37] when prescribed in combination with anticholinergics.
No differences have been found for the onset times between short acting and long acting β2
agonists. Thus, long acting β2 agonists are prefered as the baseline therapy [38].
1.1.4.3 Anticholinergics
Anticholinergics are the second group of bronchodialators used in the therapy of COPD. While
β2 agonists play a role in the active relaxation of airway smooth muscle cells, anticholinergic
drugs prevent smooth muscle cells from contracting due to parasympatic stimulation (see figure
5).
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Anticholinergics such as Ipratropium or Tiotropium have been shown to have an additional effect
in when used in combination with β2 agonists. This effect can be seen in an increase of both
the FEV1 and the FVC [40]. These effects seem to be even stronger with Tiotropium compared
to Ipratropium [41]. In addition to the short term effect of bronchodialation, Ipratropium has
been shown to increase lung function baseline levels for both values (FEV1, FVC). This effect
is greater in patients that quit smoking and can not be seen in this amount in current smokers
[42]. Another effect of Ipratropium treatment is an increased oxygen saturation during the
night as well as a better sleep quality combined with prolonged REM phases [43].
1.1.4.4 Inhaled glucocorticosteroids
In more severe cases of COPD inhaled glucocorticosteroids (ICS) are an important part in the
therapeutic approach, even more so in patients that suffer from frequent exacerbations.
ICS have been shown to increase FEV1 during the first few months of treatment. This effect is
strongest in ex-smokers and women. After this time however, lung function starts to decline in
the same manner as in the placebo controlled group [44]. There is conflicting data on whether
inhaled glucocorticosteroids have a significant effect on mortality. A recent overview [45] has
shown no difference in mortality in several double blind studies, while in other studies such as
[46], a reduced mortality rate has been found. In addition, inhaled glucocorticosteroids have
been described to reduce exacerbations [45], [47]. There is however a higher rate of pneumonia
in patients treated with ICS alone or in combination with β2 agonists than in patients treated
with β2 agonists alone [48].
This is one of the main reasons why they are only used to treat patients with moderate and
severe COPD.
1.1.4.5 Phosphodiesterase-Inhibitors (PDE4-Inhibitors)
A relatively new development in the treatment of COPD is the use of PDE4-Inhibitors such as
Roflumilast and Cilomilast. In placebo controlled trials these PDE4-Inhibitors have been shown
to increase FEV1 as well as FVC. Furthermore reduced exacerbation rates have been found
[49], [50]. An increase in lung function values has also been demonstrated in the combined
treatment with both β2 agonists as well as in combination with anticholinergics. The increase
in lung function with the combined treatment is significant compared to the treatment with
either substances alone [51].
1.1.4.6 Other possible treatment options
Methylxantines
Theophylline is a drug only used as a third line therapy in all stages of COPD. It has been
shown to improve lung function in COPD patients, but to a be less effective here than long
acting β2 agonists. It nevertheless has been found to show significant effects when used in
addition to β2 agonists. [52]. Low dose Theophyllin in combination with ICS has shown a
significantly greater increase in FEV1 than either substance alone [53].
Mycolytic Substances
The mucolytic substances used in the treatment of COPD according to GOLD [2] are N-
Acetylcysteine and Carbocisteine. These substances have not shown any improvement in lung
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function such as FEV1 or FVC, but in patients not treated with ICS treatment with mucolytic
substance has shown to decrease the rate of exacerbations [54], [55].
Physiotherapy
Patients with COPD benefit from dedicated physiotherapy. Physiotherapy has been shown to
increase FVC as well as 6 minute walking distance. It also decreases subjective dyspnoe and
reduces the rate of exacerbations [56].
1.2 Inflammatory response
1.2.1 The role of Inflammation in COPD Development
1.2.1.1 Innate immune system
The innate immune system is usually the first one to react to stimuli. The cells from the innate
system that have the greatest effect on COPD development are neutrophils and macrophages.
Neutrophils
Neutrophilic granula contain several degrading proteins. The most commonly known one to
play a role in the development of COPD is neutrophilic elastase. In addition also proteinase-3
(PR-3) is produced in neutrophils and has been found to have an even greater effect in emphy-
sema development in hamsters than elastase [58]. However, only a weak correlation between
emphysema development and lung function has been described [13]. It is thus not surprising
that even though the number of neutrophils in sputum is increased in patients with COPD [59]
there is only a weak inverse correlation between the neutrophil count in bronchoalveolar lavage
(BAL) and either FEV1 or the health status of patients. No association between neutrophil
counts and emphysema, exacerbation rates or systemic inflammation has been found [60].
Gene expression of chemoattractants for neutrophilic migration were up regulated shown by
several markers such as epithelial-derived neutrophil attractant-78 (CXCL5), interleukin-8,
LTB4, CXCR1 and CXCR2 [61]. In addition, some of these markers were found to increase in
case of COPD exacerbations such as LTB4 and 8-isoprostane. No correlation between airway
obstruction (determined by FEV1) and the concentration of the markers mentioned above,
could be determined [62].
8-isoprostane has been described to increase IL-8 expression in human macrophages [63].
In conclusion, it has been shown that neutrophils play an important role in the development
of emphysema. Since emphysema however has little effect on FEV1, these effects often are
underrated.
Macrophages
Macrophages however seem to play the more important role in the development of COPD. Severe
emphysematous destruction of lung tissue has been shown to be associated with an increase of
the absolute numbers of macrophages [64]. It has been demonstrated that MMP12 (matrix-
metalloproteinase 12) deficient mice fail to develop emphysema after cigarette smoke exposure
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Figure 6: Immune cells in the development of COPD taken from the review by Barnes [57], where an overview for the
roles of different cell types was given. Figure reprocessed from [57].
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[65]. DiStefano et al. have shown an increased number of macrophages in bronchoalveolar
lavage (BAL) of COPD patients. In addition an inverse correlation between the number of
macrophages and FEV1 was discovered [59]. MMP12 seems to be one of the most important
factors in emphysema development. Thus, not only the number of total macrophages in the
lung is important, but also their activation which was determined by MMP12 expression is. It
has been shown that the number of MMP12 expressing macrophages was increased in both
BAL samples as well as in biopsy samples, which was determined by immunohistochemical
staining in COPD patients. Furthermore the intensity of the immunohistochemical staining
was greater than in control samples [66].
Macrophages can differentiate into two subtypes, M1 and M2 macrophages. In COPD patients
a suppression of M1 macrophages has been found. These changes seem to progress with COPD
development [67]. Concurring with these findings, an increase in M2 macrophages has been
found in COPD patients compared to healthy control group. A correlation between the amount
of M2 macrophages and disease severity has been found [68].
1.2.1.2 Adaptive immune system
In addition to the innate immune system, the adaptive immune system is another important
factor in the development of COPD. The main cell types of the adaptive system are B- and
T-lymphocytes.
T-Cells
T-cells are mainly devided into CD8-positive T-suppressor cells and cytotoxic T-cells as well as
CD4-positive T-helper cells. In (non smoking) COPD patients an increase in percentage of CD8+
lymphocytes was found in comparison to healthy patients. In addition, a correlation between a
higher CD4:CD8 ratio and a higher FEV1 could be established [69]. Further investigation of
subtypes of CD8 positive cells in bronchoalveolar lavage fluid obtained from COPD patients
revealed a higher number of naive T-cells as well as a lower number of memory T-cells in
comparison to smokers that show no symptoms of COPD. The comparison to healthy smokers
shows that these changes only occur in patients that are susceptible to cigarette smoke and
are not a general reaction to smoking. The changes in naive and memory T-cells seem to only
occur in lung tissue as peripheral blood samples exhibit no differences between healthy smokers
and COPD patients in the numbers of either of those cells [70].
However, not only the differences in the numbers of various subtypes of T-cells contribute to
the changes in T-cell immunity occuring in the development of COPD. It has also been found
that changes in T-cell activation due to chronic exposure to cigarette smoke affect disease
progression. Experiments were conducted where CD3 positive T-cells were taken from wild type
mice, exposed to chronic cigarette smoke, and transferred into immunodeficient mice. The latter
animals then developed changes that are pathognomonic of COPD such as accumulation of
macrophages and neutrophils. In addition, matrix degradation leading to airspace enlargement
occuring in emphysema have been described. These changes occurred independent of cigarette
smoke exposure [71].
One of the most affected subtypes in COPD development are regulatory T-cells. This cell
type has been shown to be up regulated in lung tissue of COPD patients. T-regulatory cells
were mainly located in lymphoid follicles [72]. The increase in T-reg. cells was also found in
bronchioalveolar lavage fluid in COPD patients as well as in healthy smokers. Furthermore, the
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increase was related to the number of pack years [73]. It has also been shown that regulatory
T-cells can prevent the development of B-cell infiltrates due to cigarette smoke exposure [74].
The other group of T-cells that are important in the development of COPD are the T-helper
cells. This group can be divided into several subgroups. One of these is the TH1 cells. An
increase in percentage of TH1 cells has been found in COPD patients compared to a healthy
control group. Along with these findings a decrease in TH2 cells has been discovered [75]. The
increased TH1 cells however show a decreased response to bacterial infections, which leads to
an increased rate of pulmonary infections in COPD patients [76].
The group of T helper cells that is now suspected to play the most important role in the
development of COPD are TH17 cells. An increase of TH17 cells has been found in COPD
patients, both compared to healthy smokers as well as to non smokers. A correlation has been
found between the number of TH17 cells and the severity of airflow limitation and disease
severity [77], [78].
B-Cells
In addition to T-cells, B-cells contribute to the development of COPD. It has been unveiled
that the numbers of B-cells were increased in patients with COPD compared to the healthy
control group. An increase in B-cells in patients with COPD stage 2 compared to patients
with COPD stage 3 has also been shown. Furthermore, the values of percentage of FEV1 from
FEV1-predicted correlate with the number of B-cells. A more severe airway hyper-responsiveness
has been reported for patients with higher numbers of B-cells [79].
In patients with COPD as well as in a mouse model simulating COPD, B-cell follicles was
found. The B-cells forming these follicles exhibit an oligoclonal antigen-specific reaction. In
mice, the development of follicles were proven to progress over time. Additionally, the amount
of follicles correlates with airspace enlargement [80]. In order to prove that B-cells are vital for
the development of lymphoid follicles as well as for emphysema development, B-cell deficient
mice were exposed to cigarette smoke in a chronic exposure simulation. In wild type mice an
increase in inducible bronchus associated lymphoid tissue (iBALT) as well as an increase in
lung compliance and airspace enlargement was visible. These changes could not be found in
B-cell deficient mice. In addition, in vitro experiments have proven B cell-derived IL-10 to drive
macrophage activation and to also lead to MMP12 up regulation [81].
1.2.2 Ageing and Inflammation
In the previous chapters it has been described that the immune system plays an important role
in the development of COPD. In chapter 1.1.2 it was established that COPD is a disease that
mainly affects the elderly. Therefore, changes in the immune system in the course of senescence
might be a main factor in COPD pathology. Changes to the immune response in aged animals
have indeed been found. For example Kovacs et al. have shown a decrease in immunity in aged
mice compared to young animals following burn injury, resulting in a higher mortality in aged
animals [82].
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1.2.2.1 Age related changes in the innate immune system
An overview over the age related changes in the innate immune system was given, e.g., in the
review by A. Panda et al. [83].
Changes in neutrophils
Since neutrophils and their products play a key role in the development of emphysema, the
changes in neutrophils with ageing of the immune system are a very important aspect to be
considered. In broncheoalveolar lavage fluid of old and young healthy humans, it has been
demonstrated that the number of neutrophils was increased in the older humans compared to
the younger generation. In addition, the levels of both interleukin 8 as well as neutrophil elastase
were elevated. On the other hand increases in α1-antitrypsin as well as elastase inhibitory
capacity (EIC) have been described in the older test subjects [84]. As smoking was reported to
decrease anti-elastase activity [17], the increased baseline elastase leads to greater susceptibility.
Further investigation of changes in neutrophil function with ageing have not shown any changes
in migration or adhesion under basal conditions as well as after stimulation. Changes in the
activity of superoxide dismutase could not be found either. However, it has been unveiled that
in older humans the chemotaxis of neutrophils has been severely attenuated [85]. Additionally,
it has been shown that after stimulation with fMLP, superoxide production in elderly subjects
has been reduced in comparison to young controls. The latter has been demonstrated for
both, circulating as well as exudated neutrophils [85], [86]. Even though in some papers no
changes in phagocytotic function have been found, Wenisch et al. have shown a reduction
in the number of phagocytized Escherichia coli as well as of Staphylococcus aureus by aged
neutrophils. Resting neutrophils also showed an increased intracellular calcium level with age
as well as a reduced hexose uptake. In addition, a reduction in intracellular reactive oxygen
production after stimulation with S. aureus has been found, leading to impaired bactericidal
activity [87].
Changes in macrophages
The other important cell type in the innate immune system for the development of COPD is
the macrophages. As with most cells, macrophages undergo deterioration in the process of
ageing. Decreased function has been shown for chemotaxic as well as phagocytotic activity
[88]. In addition, superoxide anion production is compromised in the macrophages of old mice
compared to young animals. Furthermore, the defenses to antioxidant stimuli are decreased,
which can be seen by the decrease in superoxide dismutase activity with ageing [88]. Functional
changes have neither been found for adherence capacity nor for the release of oxidant and
inflammatory mediators. Examples of these unchaged mediators are extracellular superoxide
anion, TNF-alpha and PGE2, as well as the oxidized glutathione/reduced glutathione ratio
[88]. In addition to the changes in the cells themselves, also the external milieu impacts the
function of macrophages. By incubating macrophages, taken from young rats, with serum
from old animals, an impairment of the cells could be demonstrated. Young macrophages
incubated with serum from old animals showed impaired capacity to induce tumor necrosis
factor-alpha (TNF-α) production. Furthermore, increased basal levels of interleukin-6 (IL-6)
could be determined [89].
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1.2.2.2 Age related changes in the adaptive immune system
A good overview over the age related changes in the adaptive immune system is, e.g., given in
the review by Weng [90]
1.2.2.2.1 Age related changes in T-cells
With most cell types of the immune system the first parameter to change is the number of
cells. CD4+ T-helper cells from young healthy human subjects are predominantly composed of
CD27 and CD28 positive naive cells. In aged subjects the number of these naive cells declines
and is replaced by CD27 and CD28 negative memory T-helper cells [91]. A decrease in CD28
expressing T-helper cells in aged healthy test subjects has also been shown to correlate with a
reduction of the CD4/CD8 ratio [92].
In addition to the changes in numbers, modifications in cell function with ageing have also
been described [93]. These changes might be caused by the lower output of cells from the
bone marrow, and therefore by a longer lifetime of the cells. This could indicate that the
age of the cells themselves might be more important than the age of the individual. Haynes
et al. have reported that cells taken from old mice show a decrease of expansion in culture
as well as decreased expression levels of IL-2 compared to cells taken from young animals.
To prove that the age of the cells is the main factor for such changes, both young and old
animals were treated with an anti-CD4 antibody to destroy all T-helper cells. The cells sam-
pled after this treatment showed a better response to stimuli in both groups, leading to the
conclusion that a low output of T-lymphocytes is the main reason for the changes in function [93].
1.2.2.2.2 Age related changes in B-cells
It has been reported that the number of circulating B-cells decreases with ageing [95]. While
the absolute number of B-cells decreases, the changes in the sub-populations differ considerably.
CD27 positive B-cells are memory cells that can transform into plasma cells. The total number
of memory cells has been shown to be only marginally decreased in old individuals compared
to young ones [96]. CD5 positive B-cells are defined as B1 cells that are involved in T cell-
independent antibody production. The third important cell line in B-cells is the CD40+ cells
that are responsible for T-dependent antibody responses. In absolute numbers, both CD5+
and CD40+ B cells are reduced in elderly subjects [96]. Regarding the percentages of the three
sub-populations, a decrease in CD5+ B cells can be seen while the percentage in CD27+ B
cells increases. The percentage of CD40+ B-cells does not change significantly with ageing [96].
In addition to the changes in B-cell numbers, also the production of antibodies changes with
age. Increases in the levels of IgG and IgA have been described in aged subjects while there
were no changes in IgM [95]. In addition, an analysis of IgG subclasses was performed, where an
increase in IgG l, 2 and 3 could be observed, while no changes were detected in IgG 4 levels [95].
These changes might be linked to a down-regulation of the E2A-encoded transcription factor
E47 that has been observed in the B-cells of aged mice [97]. This transcription factor plays a
role in class switch of antibodies as well as in somatic hyper-mutation. The down-regulation of
E47 leads to reduced amounts of switched antibodies that are released by activated splenic B
cells. Similar trends have been seen in humans [97].
Furthermore, changes in antibody production occur during ageing. It has been shown that splenic
lymphocytes in older rats have a slower rate of capping and shedding of cross- linked surface
receptors than those taken from young animals. The rate of capping can be increased in young
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Figure 7: Changes in B-cell populations due to ageing. Figure taken from [94]
animals by the use of colchicine, which could not be proven for old animals. These functional
changes lead to a lower rate of lymphocytes with high density of surface immunglobuline in old
rats compared to in young animals [98].
1.2.2.3 Age related changes in cytokine levels
As already mentioned in chapter 1.2.2.1, the levels of IL-6 and TNF-α produced by cells taken
from old healthy donors are increased. In addition, also the levels of IL-1β were increased after
stimulation [99]. There are indications that these increases in cytokines might be protective as
lower levels of IL-1β, IL-6, TNF-α, IL-1Ra and IL-10 after stimulation in aged humans can be
considered a marker for increased mortality risk. Subjects with low cytokine levels have been
discovered to have twice the mortality risk compared to peers with higher levels of both pro- and
anti-inflammatory cytokine levels. It has also been found that there is a genetic predisposition
for expressing low cytokines that is associated with the IL-10 promoter gene. People with this
predisposition have a greater risk to lose the capacity to respond to stimuli [100].
In contrast to the described increase in mortality risk due to decreased cytokine levels, it has
been shown that mice that are unable to produce IL-6 have a decreased mortality when being
stimulated with lipopolysaccharide in comparison to wild type animals [101]. In wild type
animals, as described in the previous chapter, the levels of IL-6 were increased in old animals
compared to young ones [101]. Contrary to the increase of IL-6 and TNFα described above,
studies on humans have shown a defect in the induction of both IL-6 and TNFα [102] in healthy
older test subjects. This has been explained to be due to a defect in toll like receptor 1/2.
While other members of the toll like receptor family have been shown to be altered in aged
mice, this could not be found in the human subjects [102]. These findings might also account
for higher infection rates in older patients.
25
1 Introduction
1.3 Animal Models
Even though COPD is a disease mainly witnessed in humans, experiments can of course not be
conducted on human subjects as this would be in conflict with ethical guidelines. The conflict
can be solved by using animal models as a substitute for humans. However not all animals are
suited for such experiments. Some animals, such as rats are mostly insusceptible to cigarette
smoke induced emphysema [103]. Contrariwise guinea pigs seem to be very susceptible to
cigarette smoke induced emphysema [104],[105]. The problem with guinea pigs however is, that
it would take a lot of living space and equipment to conduct experiments on them.
The model that is widely used and by now a standard model for simulating cigarette smoke
induced COPD is the mouse model. Its advantages are the low costs for both the animals and
the housing, as well as well established materials and equipment. On the other hand it is very
important to find a strain of mice susceptible to cigarette smoke, as not all of them are. In the
literature the C57BL6/J mouse line has been described to be one of the strains susceptible to
cigarette smoke induced emphysema development [103], which is why these animals were used
for the experiments. Mice have been shown to tolerate cigarette smoke exposure for at least a
year, even though their activity seems to decrease. Mice only breathe through their nose, while
humans smoke through their mouths, thus eliminating the clearing effect of the nose. In mice
the clearing effect of nasal breathing seems less developed than in humans. This means that in
mice even nasal breathing of cigarette smoke shows similar effects to human cigarette smoking
[103]. Young mice have been shown to develop emphysematous changes in lung structure after
24 weeks of cigarette smoke exposure [106].
In humans women have been described to be more susceptible to cigarette smoke induced
COPD, especially in the early stages of COPD development [19]. March and al. have discovered
that an increased susceptibility in females also applies for most mouse strains [107]. For this
reason we also used female animals for the experiments. Our experiment were conducted by
the use of cigarette smoke in a smoke chamber. This method is the closest we can get to
simulating human smoking habits. In contrast to a side stream model, exposure to mainstream
cigarette smoke results in an inflammatory response, dominated by both macrophages and
neutrophils, whereas the inflammation due to side-stream smoke is dominated by macrophages
only. In addition, side-stream smoke has been shown to contain much higher levels of CO when
compared to mainstream smoke of the same particle concentration [108]. Since CO has been
shown to have a protective effect against lung inflammation, especially intra-alveolar neutrophil
infiltration, and we aimed to examine the effects of inflammageing on COPD development, we
decided against the sidestream smoke model [109].
1.4 Aim of Research
As the previous chapters have described in detail, COPD is a disease mainly caused by the body’s
inflammatory response to cigarette smoke. Also the changes in immune response occurring due
to the ageing immune system have been described above. From the epidemiologic studies it
is clear that the incidence of COPD rises with the age of the patients. The question now is
whether ageing, in particular immunoageing, makes an organism more susceptible to cigarette
smoke induced COPD, or whether this might only be the effect of cumulative exposure to
cigarette smoke. Furthermore, the physiological decline in lung function with age, may also
play a role in the high incidence of COPD amongst the old.
In earlier experiments using the same experimental set-up for cigarette smoke exposure it
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has been found that young animals develop emphysema and lung function changes after four
months of cigarette smoke exposure [81]. So, in order to determine whether old mice are indeed
more susceptible to cigarette smoke induced COPD, the changes in lung function of older
and younger animals exposed to cigarette smoke would be monitored to see if any differences
could be determined at any of the time points. If older mice were to develop changes in these
parameters earlier or more prominently compared to younger animals this would be indicative
to a greater susceptibility to cigarette smoke. Such findings would then be the starting point
for a more in depth analysis of the lungs to determine all the indicators of COPD as well as the
cause of the greater susceptibility of aged mice to COPD development.
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2 Methods and Materials
2.1 Animals & maintenance
Pathogen free female C57BL/6 mice aged 2 (8 to 10 weeks) and 12 months (56 weeks) were
quartered in chambers in groups of four. They were exposed to a 12 hour light cycle with constant
temperature between 23 and 25 degrees Celsius. Humidity levels were also kept constant. While
in housing, the animals were exposed only to filtered air in each of the chambers. The mice
were given unlimited access to food and water. Each of the four groups contained 8 animals.
All experiments were conducted under strict governmental and international guidelines and
were approved by the local government for the administrative region of Upper Bavaria.
2.2 Cigarette smoke exposure in a mouse model
The mice were exposed to 100 % mainstream cigarette smoke with a concentration of 500 mg/m3
total particulate matter, to imitate human smoking habits. To generate mainstream cigarette
smoke 3R4F cigarettes were used. A whole body exposure was performed by use of a smoke
chamber. Exposure time was 50 minutes twice per day, five days per week for up to three
months. After two months the first set of lung function tests were conducted which were
repeated after 3 months of smoke exposure (see chapter ??). Control mice were handled, but
only exposed to filtered air. 24 hours after the last cigarette smoke exposure the mice were
sacrificed.
Total particulate matter was measured by using gravimetric analysis of quartz filters before
and after air sampling from the smoke chamber and by measuring total air sample volume.
To determine the amount of CO produced by cigarette smoking, CO concentrations were
constantly measured using a GCO 100 CO meter with concentrations between 288 ± 74 ppm.
No toxic effects of CO exposure at these levels were witnessed in cigarette smoke exposed
animals, CO-Hb levels were measured at 12.2 ± 2.4 %.
Product Company
Research Cigarettes 3R4F Tobacco Research Insitute, University of Kentucky,
Lexington, KY, USA
WhatmanTM Glass microfibre
filters Diameter 25 mm
GE Healthcare UK limited, Buckinghamshire, UK
GCO 100 CO Meter Greisinger Electronic, Regenstauf, Germany
Table 5: Materials used for cigarette smoke experiments and measurements
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2.3 Lung function analysis
Lung function analysis was performed using the flexiVent System (Scireq, Montreal, Canada)
after two months and were repeated after three months of cigarette smoke exposure under
anaesthesia with a ketamine-xylasine mixture using a non-tracheotomic intubation. The mice
were ventilated with a tidal volume of 10 mL/kg with a frequency of 150 min−1 to simulate a
lung volume close to the one reached by physiological breathing. The mechanical properties,
dynamic lung compliance and resistance, were determined by using a software generated script.
Dynamic lung compliance was defined as Cdef = VTPIP−PEEP with Vbeing tidal volume, PIP
being peak inspiratory pressure and PEEP being positive end-expiratory pressure. Changes
in lung compliance occur in many diseases of the lung. Pulmonary fibrosis for example shows
a decrease in lung compliance, whereas in COPD and lung emphysema the lung compliance
increases. Airway resistance is defined as RAW = ∆P∆V . ∆p is the change in pressure, while ∆V
describes the following change in lung volume. Changes in airway resistance mostly occur when
the diameter of the airways decreases, as it is the case in COPD patients. To get a more precise
value these measurements were determined four times for each animal.
2.4 Bronchioalveolar lavage (BAL) sampling and processing
Product Company
PBS Gibco, Life Technologies, Darmstadt, Germany
RPMI-1640 Gibco, Life Technologies, Darmstadt, Germany
FCS Gibco, Life Technologies, Darmstadt, Germany
Objektträger
Table 6: Materials used for preparation of BAL
Bronchioalveolar lavage was performed by using four aliquots of 0,5 mL sterile PBS for intra-
tracheal instillation into the lungs. For the preparation of cytospins the lavaged cells were
spun down at 400 g. Afterwards cells were re-suspended in RMPI- 1640 medium in a solution
containing 10% FCS. Total cell counts were then determined using a hemocytometer. Afterwards
30 000 cells per sample were spun down onto histological slides. These slides were then stained
using the May-Grünwald-Giemsa staining as described in chapter 2.7.1. Differential cell counts
of 200 cells per sample on these slides were performed using morphological criteria.
BAL fluids were used to determine cytokine secretion via multiplex analysis.
2.5 Tissue preparation
24 hours after the last cigarette smoke exposure mice were sacrificed. In four animals of each
group the left lung was fixed by intra-tracheal instillation of 6% para-formaldehyde (PFA)
buffered with PBS with a constant pressure of 20 cm fluid column. The tissue was then
embedded in 2% agar solution to ensure the best stereological analysis possible. After hardening
of the agar around the tissue the samples were dehydrated using a Leica Tp 1020 embedding
machine. Dehydration was performed using alcohol solutions with increasing concentrations
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2.6 Fluorescence-activated cell sorting (FACS)
Product Company
PBS Gibco, Life Technologies, Darmstadt, Germany
Para-formaldehyde SigmaAldrich, St. Louis, MO, USA
Agar SigmaAldrich, St. Louis, MO, USA
Paraffin
Thermo Scientific super-frost
plus Microscope slides
Gerhard-Menzel GmbH, Braunschweig, Germany
Feather Microtome blade S35 Feather Safety Razor Co. LTD, Osaka, Japan
Table 7: Materials used for tissue praparation and cutting histological slides
(starting at 70% and increasing to 80%, 96% for a few times and then increasing to 100%)
followed by suspension in xylene. Afterwards the tissue was embedded in paraffin blocks for
cutting. The blocks were then cut using the Zeiss Microtome with Feather blades to 3 µm
thickness and mounted onto slides. The the right lung was shock frozen in liquid nitrogen and
then stored in -80°C for isolation of RNA and protein as described in chapter 2.9. The lungs of
the remaining four animals per group were used for FACS analysis as described in chapter 2.6.
In addition to the preparation of the lung, spleens from all the groups were harvested for FACS
analysis (see chapter 2.6).
2.6 Fluorescence-activated cell sorting (FACS)
For the determination of lymphocyte infiltration and analysis of subtypes whole, lung tissue
prepared as described in chapter 2.5 was used. Lungs were first perfused with sterile PBS
through the right ventricle to clear leukocytes and erythrocytes from lung circulation in order to
only analyse lung tissue. Lung homogenisation was then performed by applying lung dissociation
buffer for enzymatic digestion. Mechanical dissociation of the tissue was then performed by
use of the gentleMACS dissociator (Miltenyi Biotec). Afterwards samples were filtered to
remove large particles remaining from dissociation from the single cell suspensions. Cells were
afterwards blocked using CD16/CD32 antibodies.
The samples were split and stained for different analyses. One part of the sample was stained
with the Mouse Regulatory T-cell Staining Kit which uses an anti-FoxP3 antibody to determine
the amount of regulatory T-cells in lung tissue. The other part of the sample was centrifugated
using Pancoll for density gradient centrifugation. These samples were then used for the isolation
of mono-nuclear cells, which were then cultured over night on Anti-CD3/ Anti-CD28 coated
plates to perform intracellular cytokine staining. Restimulation with a leukocyte activation
cocktail with Golgi plug for four hours was performed the following day. Cells were afterwards
stained with anti-CD4 antibody and fixed with 2% formaldehyde solution and permeabilized
with 0.3% saponin buffer for intracellular staining. To distinguish the different T-helper cell sub-
populations the cells were stained with antibodies against IL-17A, IFNγ and IL-4. Differentiation
was performed using multicolour analysis of the stained cells with a BD FACSCanto II flow
cytometer and BD FACSDiva software.
Spleens sampled as described in chapter 2.5 were homogenized mechanically by using the
gentleMACS Dissociator and afterwards filtered to remove larger particles and obtain a single
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Product Company
PBS Gibco, Life Technologies, Darmstadt, Germany
Lung Dissociation Buffer Miltenyi Biotec, Bergisch Gladbach, Germany
Gentle MACS Dissociator Miltenyi Biotec, Bergisch Gladbach, Germany
Mouse Regulatory T Cell Stain-
ing Kit
eBioscience, San Diego, CA, USA
Pancoll PAN Biotech, Aidenbach, Germany
Anti-CD3/ Anti CD28 coated
plates
Golgi Plug BD Pharmingen, San. Diego, CA, USA
Formaldehyde Aldrich Chemistry, St. Louis, MO, USA
0.5% Saponin Buffer Sigma Aldrich, St. Louis, MO, USA
Anti- Mouse Anti-CD4 Antibody eBioscience, San Diego, CA, USA
Anti- Mouse Anti-IL17A Anti-
body
eBioscience, San Diego, CA, USA
Anti- Mouse Anti-IFN Antibody eBioscience, San Diego, CA, USA
Anti- Mouse Anti-IL4 Antibody Biozol, Eching, Germany
Anti- Mouse Anti-CD16/CD32
Antibody
Biozol, Eching, Germany
Anti- Mouse Anti-CD44 Anti-
body
eBioscience, San Diego, CA, USA
Anti- Mouse Anti-CD69 Anti-
body
eBioscience, San Diego, CA, USA
Anti- Mouse Anti-CD62L Anti-
body
eBioscience, San Diego, CA, USA
BD FACSCanto II Flow Cytome-
ter
BD Biosciences, Heidelberg, Germany
Table 8: Materials used for FACS-analysis including antibodies
cell suspension. Splenocytes were blocked by using CD16/ CD32 antibodies before being stained
with anti-mouse anti-CD4, anti-CD44, anti-CD69 and anti-CD62L antibodies. The stained cells
were afterwards analysed by using a BD FACSCanto II flow cytometer running BD FACSDiva
software.
2.7 Histological staining
2.7.1 May-Grünwald-Giemsa staining
Slides prepared as described in chapter 2.4 were dried over night at 38 ◦C and stained the next
day. After labelling the slides, they were suspended in May-Grünwald’s eosine-methylene blue
solution for 10 minutes. Afterwards the slides were be rinsed in tap-water. The next step was
suspending the slides in Giemsa’s Azur-eosine methylene blue solution, diluted 1:20 using tap
water, for 15 minutes. Afterwards slides were rinsed in tap water again and dried off at room
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Product Company
May-Grünwald’s eosine-methylene blue solution modified Merck, Darmstadt, Germany
Giemsa Azur-Eosine methylene blue solution Merck, Darmstadt Germany
Entellan New Merck, Darmstadt, Germany
Coverslips 18×18 mm Thickness No. 1 VWR, Darmstadt, Germany
Table 9: Materials used for May-Grünwald-Giemsa staining
temperature. To protect the stained tissue, the slides were covered using Entellan mounting
medium and cover slides.
2.7.2 Haematoxylin-Eosin staining
Product Company
Eosin yellowish Merck, Darmstadt, Germany
Mayer’s Hemalaun Merck, Darmstadt Germany
Hydrochloric acid (HCl) Merck, Darmstadt, Germany
Xylene Roth, Karlsruhe, Germany
Entellan New Merck, Darmstadt, Germany
Coverslips 24×50 mm Thickness No. 1 VWR, Darmstadt, Germany
Table 10: Materials used for HE staining
The slides (prepared as described in chapter 2.5) were stored over night at 38°C before staining.
For staining the tissue, it was necessary to remove the paraffin first. To this end the slides
were first deparaffinized by suspending them in pure xylene for two times 5 minutes. As the
staining was performed in hydrophilic solutions the tissue needed to be rehydrated. Rehydration
was achieved by suspending the slides in solutions of ethanol with decreasing concentrations
(100%, 100%, 90%, 80%, 70% 1 minute in each solution) and then rinsed in distilled water.
Afterwards the nuclei of the cells were stained using Mayer’s Haemalaun solution for 5 minutes
and afterwards differentiated using a solution of 1% HCl-ethanol for 2 minutes. After rinsing
the slides in both tap-water and distilled water, the slides were stained with a ready to use
eosin solution for 8 minutes. Since the preservation of the tissue was done with a xylene based
substance, a dehydration of the tissue was necessary. This was achieved by placing the slides in
solutions of ethanol with increasing concentrations (70%, 80%, 90%, 96%, 100%, 100% each for
1 minute). Afterwards slides were placed in pure xylene for two times 5 minutes. To protect
the tissue, cover-slips were then mounted using Entellan.
2.7.3 Trichrome staining
Slides were prepared as described in chapter 2.5 and stored over night at 38°C. as described
before, the tissue needed to be deparaffinated before staining. This was achieved by suspending
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Product Company
Weigert Iron Hematoxylin A+B Merck, Darmstadt, Germany
Ponceau 2R Sigma Aldrich, St. Louis, MO, USA
Acid fuchsin Merck, Darmstadt, Germany
Acetic Acid Merck, Darmstadt, Germany
Phosphomolybdic acid Merck, Darmstadt, Germany
Orange G Merck, Darmstadt, Germany
Light Green SF Merck, Darmstadt, Germany
Xylene Roth, Karlsruhe, Germany
Entellan New Merck, Darmstadt, Germany
Coverslips 24×50 mm Thickness No. 1 VWR, Darmstadt, Germany
Table 11: Materials used for Masson’s-Trichrom staining
the slides in pure xylene for two times 5 minutes. Afterwards rehydration of the tissue was
performed by placing the slides in solutions of ethanol with decreasing concentrations (100%,
100%, 90%, 80%, 70% each for 1 minute). Afterwards slides were directly placed into ready
to use Weigert’s iron hematoxylin solution for 4 minutes. Differentiation was performed in
1% HCl-ethanol solution. The slides were then rinsed in tap water. Afterwards slides were
suspended in Ponceau-acid-fuchsin solution for 5 minutes and then washed in a solution of 1%
acetic acid. In the next step slides were stained with phosphomolybdic acid- orange G solution
for 7 minutes and again washed in 1% acetic acid solution. The last staining was performed
with light green solution for 10 minutes. Afterwards the slides were to be washed in distilled
water and then dehydrated using ethanol solutions with increasing concentration (70%, 80%,
90%, 96%, 100%, 100% each for 1 minute). After suspending the slides in pure xylene for two
times 5 minutes, coverslips were mounted with Entellan.
2.7.4 Immunohistochemistry
Immunohistochemical staining of the lung tissue was also performed. Slices were cut to 3 µm
thickness as described in chapter 2.5 and stored at 58°C over night. For deparaffinization of the
tissue, the slides were suspended in pure xylene for two times 5 minutes. Afterwards rehydration
was necessary because all the staining solutions are hydrophilic. This was achieved by putting
the slides in solutions of ethanol with decreasing concentration (100%, 100%, 90%, 80%, 70%,
each for 1 minute). The slides were then rinsed in distilled water. Endogenous peroxidase
activity was then blocked by placing the slides in a solution of 1.8% H2O2 (in 80% methanol
and 20% distilled water) for 20 minutes. A heat induced epitope retrieval was performed in
ready to use HIER Citrate Buffer, diluted as given by the manufacturer, in a De-cloaking
chamber. The slides were first heated up to 125 ◦C and then allowed to cool down to 90 ◦C.
After removing the container of slides from the de-cloaking chamber, they were left to cool
down for another ten minutes at room temperature. Afterwards the slides were further cooled
down by exchanging half of the hot citrate buffer with room temperature Rockland buffer.
This is repeated four times. To prevent unspecific binding of antibodies, tissue blocking was
performed using rodent blocking antibody for 30 minutes. The slides were then washed in Wash
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Product Company
Xylene Roth, Karlsruhe, Germany
Hydrogenperoxide (H2O2) solution Sigma Aldrich, St. Louis, MO, USA
HIER Citrate Buffer pH 6.0 ZUC 028 Zytomed Systems, Berlin, Germany
Decloaking chamber Biocare Medical, Concord, CA, USA
Rodent Block M Biocare Medical, Concord, CA, USA
Rockland 10× TBS buffer pH 7,5 Rockland, Limerick, PA, USA
TRIS Wash Buffer TBS 20× ZUC 066 Zytomed Sytems, Berlin, Germany
Rabbit On Rodent AP-Polymer Biocare Medical, Concord, CA, USA
Rat on Mouse AP-Polymer Biocare Medical, Concord, CA, USA
Vulcan Fast Red Chromogen Kit Biocare Medical, Concord, CA, USA
Haematoxylin Sigma-Aldrich St. Louis, MO, USA
Table 12: Materials used for immunohistochemistry
Target Dilution Origin Company
MMP12 1:400 rabbit Abcam, Cambridge, UK
CD3 1:300 rabbit Sigma Aldrich, St. Louis, MO, USA
CD21 1:100 rabbit Novus Biologicals, Littleton, CO, USA
CD45R/B220 1:50 rat BD Pharmingen, San Jose, CA, USA
IL17 1:100 rabbit Santa Cruz Biotechnology, Dallas, Texas, USA
P16 1:50 rabbit Santa Cruz Biotechnology, Dallas, Texas, USA
SIRT1 1:100 rabbit Merck Millipore, Darmstadt, Germany
β-Galactosidase 1:150 rabbit life Technologies, Eugene, OR, USA
Table 13: List of antibodies used for immunohistochemistry
buffer (ZUC 066) by placing them in the buffer for 2 minutes each in 3 different containers.
Afterwards tissue was incubated with primary antibody, diluted as given in table 13 with
antibody diluent, for at least 8 hours at 4°C. After incubation with the primary antibody, slides
were washed in ZUC66 buffer as described above. Afterwards they were incubated with an
alkaline phosphatase labelled secondary antibody directed at the primary antibody (Rabbit On
Rodent, Biocare Medical or Rat on Mouse, Biocare) for 30 minutes. Again slides were washed
with ZUC66 buffer. Afterwards signals were intensified using chromogen substrate Vulcan Fast
Red, prepared as given by the manufacturer and incubated for 7 to 12 minutes. After washing
in ZUC66 buffer and rinsing in distilled water, slides were counter-stained with a ready to use
hematoxylin solution for three minutes. Afterwards the slides needed to be washed again and
were placed in the buffer for 5 minutes to drain excess colour. As the slides were covered using
a xylene based mounting medium, the tissue needed to be dehydrated. This was performed
by placing the slides in solutions of ethanol with increasing concentrations (96%, 96%, 100%,
100% for 1 minute each) and then placed in pure xylene for two times 5 minutes. Slides were
then protected by mounting cover-slips with a Entellan.
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2.8 Stereological analysis
Stereological analysis was performed on tissue of the left lung of the mice. Slides were analysed
using an Olympus BX51 light microscope equipped with a computer-assisted stereological
toolbox (NewCAST, Visiopharm, Hoersholm, Denmark).
2.8.1 Mean Chord Length
Emphysema development was quantified by measuring the mean linear intercept or mean
chord length (MCL) and alveolar surface area in HE stained slides (prepared as described in
chapters 2.5 and 2.7.2). Measurements were performed on 30 random fields of view with 20
× magnification using a superimposed grid (see Figure 8). Intercepts of the blue lines with
alveolar septa as well as any of the red ticks falling on alveolar airspace were counted for the
calculation of MCL as follows:
MCL = 2·ΣPair ·L(p)ΣIsepta
[µm] (2.1)
Red ticks of the grid hitting alveolar airspace are labeled Pair, length per point L(p) is the
distance between two red ticks, while the intersections of the grid with alveolar walls are labeled
Isepta. In equation 2.1 the sum is taken over all fields of view.
Figure 8: Screen-shot of newCAST grid for MCL counting, Blue lines for intercept with alveolar septa, red ticks for
quantification of air space
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2.8.2 Inducible Bronchus Associated Lymphoid Tissue
A stereological analysis of the volume of inducible bronchus associated lymphoid tissue (iBALT)
was performed. For quantification a different grid was superimposed on 100 fields of view of
HE stained lung tissue with a magnification of 40 × (see Figure 9). Points (yellow) falling on
iBALT structures were counted as PiBALT to determine iBALT volume, while lines intersecting
with basal membrane of either airways or vessel were defined as Iairway+vessel to quantify basal
membrane area. The amount of iBALT structures in relation to basal membrane area was
defined as:
(
V
S
)
iBALT
= ΣPiBALT ·L(p)ΣIairway+vessel
[
µm3
µm2
]
(2.2)
Figure 9: Screen-shot of newCAST grid for iBALT counting, lines for intercept with basal membrane of either vessel or
airway, points for counting of iBALT volume
2.8.3 Airway Remodelling
Furthermore, counting of collagen fibres was conducted to quantify the degree of airway
remodelling. Counting was performed on lung tissue prepared as described in chapter 2.5 and
stained as described in chapter 2.7.3. Again a special grid was superimposed on 100 fields of
view with a magnification of 40× (Figure 10). Collagen was counted only around airways, not
around vessels, these points being defined as Pcollagen. Lines intersecting with either airway or
vessel basal membrane were defined as Iairway+vessel.
(
V
S
)
Collagen
= ΣPCollagen·L(p)ΣIairway+vessel
[
µm3
µm2
]
(2.3)
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Figure 10: Screen-shot of newCAST grid for quantification of airway remodelling, lines for counting of intersections with
basal membrane of vessels and airways, points for quantification of collagen fibre volume
2.9 cDNA Transcription and Quantitative Real Time PCR
Frozen tissue of the right lung was homogenised by use of Micro-Dismembranator-S for 1 min at
3000 min−1. Homogenised tissue was then dissolved in Roti-Quick 1 Solution. After adding Roti-
Quick 2 Solution and extracting RNA from the homogenate further extraction was performed
using the peqGOLD Total RNA Kit according to the instructions given in the kit. Synthesis of
cDNA was performed using Random Hexamers and MuL V Reverse Transcriptase.
Expression of target genes (see table 14) was determined in comparison to housekeeping control
hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT-1) using Platinum SYBR Green
qPCR SuperMix and StepOnePlusTM 96 well Real-Time PCR System (Applied Biosystems).
Primers (see table 14) were designed by the use of Primer-BLAST software according to
published mRNA sequences.
Relative transcript expression of genes is defined as 2−∆Ct = 2Cttarget−Ctreference , comparison to
control group was defined as 2∆∆Ct = 2∆Cttreated−∆Ctcontrol
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Gene Forward Primer Reverse Primer
CXCL 13 TCT CTC CAG GCC AGG CAT TTC T ACC ATT TGG CAC GAC GAT TCA C
F4/80 CTC TGT GGT CCC ACC TTC AT GAT GGC CAA GGA TCT GAA AA
Foxp3 AGA GCC CTC ACA ACC AGC TA CCA GAT GTT GTG GGT GAG TG
Gata 3 GTC ATC CCT GAG CCA CAT CT TAG AAG GGG TCG GAG GAA CT
HPRT 1 CCT AAG ATG AGC GCA AGT TGA A CCA CAG GAC TAG AAC ACC TGC TAA
IFN TCC AGA GCT GCA GTG ACC GAA GCA CCA GGT GTC AAG
IL-6 GTT CTC TGG GAA ATC GTG GA TGT TCA CCA GGT AGC TAT GG
IL-13 TAC GGT CTC CAG CCT CCC CG GGC CGT GGC GAA ACA GGT GC
KC (CXCL 1) CCG AAG TCA TAG CCA CAC GTG CCA TCA GAG CAG TCT
MIP1 CAC CAT ATG GCT CGG ACA CC TCA GGA AAA TGA CAC CTG GCT
MMP12 TGT ACC CCA CCT ACA GAT ACC TTA CCA TAG AGG GAC TGA ATG TTA CGT
p16 TCG TGA ACA TGT TGT TGA GGC CTA CGT GAA CGT TGC CCA TC
p21 CGG TGT CAG AGT CTA GGG GA AGA GAC AAC GGC ACA CTT TG
Rorγt CAA GTC ATC TGG GAT CCA CTA C TGC AGG AGT AGG CCA CAT TAC A
SIRT1 CCA TTA ATG AGG AAA GCA ATA GGC AAT ACA AGG CTA ACA CCT TGG G
TNF-α CAC CAC GCT CTT CTG TCT GGC TAC AGG CTT CTG ACT C
Muc5AC ATC GAG AGG ACG GTT GAC AC ATC CAG CCT TGC TTG
Table 14: List of primers for quantitative real time PCR
Product Company
Micro-Dismembranator-S Sartorius, Göttingen, Germany
peqGOLD Total RNA Kit Peqlab, Erlangen, Germany
Roti Quick Kit Roth, Karlsruhe, Germany
MuL V Reverse Transcriptase Applied Biosystems, Darmstadt, Germany
Platinum SYBR Green qPCR SuperMix Applied Biosytems, Carlsbad, CA, USA
Random Hexamers Applied Biosytems, Carlsbad, CA, USA
StepOnePlusTM 96 well Real-Time PCR System Applied Biosystems, Carlsbad, CA, USA
Table 15: Materials for tissue homogenisation, isolation of RNA, production of cDNA and quantitative real time PCR
2.10 Protein isolation and Western Blot
The shock frozen lung tissue prepared as described in chapter2.5 was homogenized as described
in chapter 2.9. A small portion of the still frozen lung tissue powder was then dissolved in
RIPA-Buffer (prepared as described in table 17). After thorough mixing, the solution was
centrifuged and the supernatant taken for further analysis.
2.10.1 Protein concentration analysis
Protein concentration was then determined using the BCA assay kit, in comparison to a
standard curve with known concentrations of bovine serum albumin ranging from 2 mg/mL to
a blank that only contained RIPA buffer.
Protein probes were diluted 1:10 in RIPA buffer for more accurate analysis. For each of the
probes 25 µL of the diluted protein solution were taken into micro-plane wells with 200 µL of
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Product Company
Albumine from bovine serum (BSA) SigmaAldrich, St. Louis, MO, USA
Laemmli sample buffer BioRad Laboratories, Hercules, CA, USA
Rotiphorese Gel 30 (37,5:1) Roth, Karlsruhe„ Germany
SDS Solution 10% AppliChem, Darmstadt, Germany
BioRad Precision Plus Protein Dual Color Standards BioRad Laboratories, Hercules, CA, USA
TEMED 20 BioRad Laboratories, Hercules, CA, USA
Milkpowder, Blotting Grade Roth, Karlsruhe, Germany
ECL Prime Western Blotting Detection Reagent GE Healthcare, Munich, Germany
Immun-Blot PVDF Membrane for Protein Blotting BioRad Laboratories, Hercules, CA, USA
Table 16: Materials used for protein isolation ans western blot
Ingredient Concentration
Sodiumchloride (NaCl) 150 mM
Tris 10 mM pH 7.2
SDS 0.1%
Triton X-100 1%
Deoxycholat 1%
EDTA 5 mM
Complete Protease Inhibitor 1:25
Vandate 1:100
Table 17: RIPA buffer recipe and ingredients
Ingredient Amount
Tris 15.1 g
SDS 50 mL
Glycin 94 g
Distilled water 900ml
Table 18: Electrophoresis buffer recipe to be diluted 1:5 in distilled water and ingredients
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Ingredient Amount
Methanol 200 mL
Tris 2.42 g
Glycin 11.2 g
Distilled water 800 mL
Table 19: Transfer buffer recipe
working reagent added for analysis. The plate was then incubated for 45 min at a temperature
of 37 °C before analysis.
2.10.2 Western Blot
In preparation for the western blot analysis, gels were prepared the previous day to ensure
complete polymerisation of the gel. The gels were prepared using BioRad glass plates with a
thickness of 1,5 mm (the lower part consisting of separation gel and the upper part consisting
of collection gel) and 15 wells for protein solution.
The following day gels were washed and placed in running buffer prepared as described in table
18 and afterwards the wells were loaded with the protein solution prepared as described in
chapter 2.10.1. The first well of each gel was filled with marker protein. The gels were run with
400 mA and 100 V for 10 min to pass the protein through the collection gel and afterwards for
then run for approximately 60 min to be separated.
After separation, the protein was transferred onto the membrane, that had been activated in
methanol and placed onto the gel. The transfer was performed in cooled transfer buffer (see
table 19) with 400 mA and 100 V for about 70-85 min. The membrane was afterwards washed
in PBST and blocked in a solution of 5% milk (5 g milk-powder diluted in 100 mL of PBST).
The membrane was again washed in PBST and incubated over night at 4°C with the primary
antibody that was diluted according to table 21 in 1% milk solution.
After incubation for at least 8 hours, the membrane was washed and incubated with the
secondary antibody diluted in 1% milk solution for an hour at room temperature. After another
round of washing with PBST, the membrane was covered with blotting reagent and pictures
were taken as described in chapter 2.10.3.
For the determination of β-actin the membrane was washed and stripped by incubating with
a ready to use stripping buffer for 15 minutes at room temperature, washed again and then
blocked in 5% milk solution for 30-60 min. After blocking the membrane was incubated with
β-actin antibody diluted in 1% milk solution for an hour at room temperature. Afterwards the
membrane was washed and then developed using the Amersham ECL detection reagent and
photographed (see chapter 2.10.3).
2.10.3 Analysis of Western Blot
For the analysis of the western blot membranes, pictures were first taken with a ChemiDocTM
XRS+ with Image Lab TM Software. The chemiluminescent pictures were taken with different
exposure times depending on the antibody used. To also be able to determine the size of the
protein bands, an image under white light of the markers was taken and merged with the
luminescence image. Analysis was then using the same software to quantify the intensity of
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Ingredient CG SG Company
Distilled Water 5.6 mL 5.8 mL
Tris Buffer 1,5 M, pH 8.8 4.2 mL
Tris Buffer 0,5 M, pH 6.8 2.5 mL
Rotiphorese Gel 30 (37,5:1) 6.6 mL 1.7 mL Roth, Karlsruhe, Germany
SDS 165 µL 100 µL AppliChem, Darmstadt, Germany
TEMED 20 22 µL 20 µL BioRad Laboratories, Munich, Germany
Ammoniumpersulfat (APS) 22 µL 20 µL Sigma-Aldrich, St. Louis, MO, USA
Table 20: Separation (SG) and collection gel (CG) recipes and ingredients
Target Dilution Origin Company
SIRT1 1:1000 rabbit Millipore tenucula, CA, USA
p16 1:200 rabbit Santa Cruz Biotechnology, Dallas, Texas, USA
p21 1:200 rabbit Santa Cruz Biotechnology, Dallas, Texas, USA
p53 1:200 mouse Santa Cruz Biotechnology, Dallas, Texas, USA
Table 21: List of antibodies used for Western blot
the luminescence bands, which was then compared to the luminescence emitted by the β-actin
band on the same membrane after stripping.
2.11 Data analysis
For all the data analyses GraphPad Prism 6 software (GraphPad Software, La Jolla, USA) was
used. The results are given as mean values, while the error bars indicate the standard deviation.
To determine the significance of the results, One Way ANOVA tests were used to compare
multiple groups. For One Way ANOVA, as for most statistical analyses, Gaussian distribution
is required, so tests for normality were performed.
For some of our experiments we had to distribute the mice into two groups, because there was
not enough tissue to perform all analyses on all mice. Therefore, for some analyses the number
of values (N) was very small. This of course limits the credibility of a statistical analysis. The
test for Gaussian distribution with the applied software package requires a minimum number of
N= 8. Thus, for most of our tests, normal distribution could not be tested. We nevertheless
assumed Gaussian distribution in all our analyses, since it was proven for all the analyses
that had a number of N large enough to carry out the test. As lung function analysis was
performed on all animals undergoing the experiment, the tests for Gaussian distribution have
been performed on the lung compliance measurement. With a p-value ranging from 0.4 to 0.84
after two months of smoke exposure, the test was positive such that a Gaussian distribution
can be assumed, or at least could not be disproved.
Although the number of test subjects in our experiment was small, we still reached significant
results in most of the analyses performed.
In the figures presenting the results significant differences are marked with stars, the number of
which indicate the p values of the statistical analysis used to determine significance. Any p
value greater than 0.05 was considered not significant (ns).
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ns p ≥ 0.05
* p ≤ 0.05
** p ≤ 0.01
*** p ≤ 0.005
**** p ≤ 0.001
As the experiment was designed with two independent variables, one being the age of the
mice and the other being the exposition to cigarette smoke, a Two-Way-ANOVA analysis for
the statistics of the data might be considered an optimal solution. To show that the results
are quite robust independent of the applied method, for some of the data Two-Way-ANOVAs
were performed additionally. The data sheets are presented below. For all other results,
One-way-ANOVA was performed as presented in chapter 3.
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Results of lung function analysis after 3 months of smoke
exposure analysed with One-Way-ANOVA
Results of lung function analysis after 3 months of smoke
exposure analysed with Two-Way-ANOVA
Results iBALT analysis with One-Way-ANOVA
Results iBALT analysis with Two-Way-ANOVA
Results of FACS counting of Th17 cells analysed with One-
Way-ANOVA Results of FACS counting of Th17 cells analysed with One-
Way-ANOVA
Figure 11: Comparison between the results of analysis with One-Way-ANOVA and Two-Way-ANOVA
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3.1 Lung Function Analysis
After two months of cigarette smoke exposure, lung function analysis was performed, as
described in chapter 2.3. The objective was to investigate whether any differences in lung
function between the groups occur due to cigarette smoke exposure. The most important
markers of COPD development that can be determined in mice are lung compliance and airway
resistance [110]. Accordingly these two markers were examined to determine the effects of
cigarette smoke exposure. The data determined after two months of cigarette smoke exposure
suggested no changes in lung function due to cigarette smoke exposure in either the young
mice, or the old animals. However the baseline compliance in old, filter air exposed animals
was significantly higher compared to the younger peer group (figure 12).
Figure 12: Lung compliance analysis after two months of smoke exposure: No significant changes between either the
groups of young mice or the groups of old mice. The lung compliance of old mice is larger than that of the young animals.
As we had used a non-fatal method of intubation for this lung function test, we were able to
continue the smoking experiments using the same mice for another month. After a total of
three months of smoke exposure, the lung function tests were repeated. In the analysis of lung
compliance, a significant increase for the old animals was determined, as can be seen in figure 13.
Even though changes in lung function parameters could be determined in the old mice at this
time-point, there still were no significant changes in the lung compliance of young animals due
to cigarette smoke exposure. As has already been found after two months of cigarette smoke
exposure, the baseline compliance for the old filter air exposed (FA) animals was increased
compared to young FA animals (figure 13).
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Figure 13: Lung compliance analysis after 3 months of cigarette smoke exposure. A significant increase in lung
compliance in old animals due to cigarette smoke can be seen while there was no increase in lung compliance in young
animals.
3.2 Stereological Analysis
3.2.1 Mean Chord Length
As emphysema development is one of the most important markers for the development of COPD,
its quantification is very important to monitor the progress of the disease in our cigarette smoke
mouse model. Changes between the groups are obvious from the HE-stained tissue (Figure
14). Quantification was performed as described in chapter 2.8.1. As shown in Figure 15, a
significant increase in the mean chord length has been found already in the filter-air-exposed
(FA) old mice compared to FA young animals, while no significant changes were observed in
the young filter air exposed mice (white bars) compared to young mice with CS-exposure (dark
grey bars). Most importantly, our analysis showed that there was a significant increase in the
mean chord length in old CS-exposed animals (black bars) in comparison with the FA-exposed
animals of the same age group (light grey bars) as well as in comparison with the CS- exposed
animals in the group of young mice .
3.2.2 Airway Remodelling
Another mechanism in the development of COPD is small airway remodelling, which can be
quantified by the increase in collagen fibres around the airways. Airway remodelling is partly
responsible for the obstructive component in the COPD development, as the increase in collagen
fibres is taking part in the decrease in airway area. As visible in figure 17, with lung tissue
stained as described in chapter 2.7.3. Here an increase in the green stained collagen fibres in the
airway walls can be found only in the old cigarette smoke exposed animals. Further analysis
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young filter air exposed mice
old filter air exposed mice
young CS exposed mice
old CS exposed mice
Figure 14: Lung tissue of the mice described in chapter 2.1 stained with HE as detailed in chapter 2.7.2. For the young
animals no changes in airspace volume due to cigarette smoke exposure are visible. The old animals exhibit an increased
airspace already in the filtered air exposed groups. Airspace enlargement increases due to cigarette smoke exposure in
only old animals.
of these stainings were analysed as described in chapter 2.8.3 (figure 16). Here only a small,
non-significant increase in airway collagen could be detected in the young animals after three
months of cigarette smoke exposure. In contrast to those findings, in the old animals there
is a significant increase in airway collagen due to cigarette smoke exposure. In addition an
increased baseline in the old animals can be detected, but it does not reach significant levels.
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Figure 15: Mean chord length, determined by using the CAST-sytem as described in chapter 2.8.1. A significant increase
due to cigarette smoke exposure is seen only in the case of the old mice. Additionally, a baseline increase in old filter air
exposed mice can be detected.
Figure 16: CAST-analysis of airway remodelling shows a significant increase due to cigarette smoke exposure in the old
mice. In addition a significant difference can be seen in old and young cigarette smoke exposed animals.
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young filter air exposed mice
old filter air exposed mice
young CS exposed mice
old CS exposed mice
Figure 17: Lung tissue stained with Masson’s Trichrom staining as described in chapter 2.7.3 to show airway remodelling
in the amount of collagen around the airways. A significant increase in collagen fibres (green) can only be detected in old
cigarette smoke exposed animals.
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3.2.3 Inducible Bronchus Associated Tissue
As described in previous papers [81] inducible Bronchus Associated Lymphoid Tissue (iBALT)
plays a very important role in the development of COPD and the destruction of alveolar tissue
in the progress of the disease. Figure 18 shows a significant increase in iBALT structures for
cigarette smoke exposed old mice compared to old filter air exposed animals and to young
cigarette smoke exposed mice. A slight, but not significant increase was visible in case of the
young animals due to cigarette smoke exposure. Such slight changes can also be seen in the old
filter air exposed animals where a negligible rise in the amount of iBALT structures was visible
compared to both groups of young animals.
Figure 18: Volume of iBALT structures was determined by using the CAST-sytem as described in chapter 2.8.2. A
significant increase in iBALT volume can be seen only in cigarette smoke exposed old animals compared to both, the
filter air exposed peers and the cigarette smoke exposed young animals.
As we suspected these structures to be lymphoid tissue, immunohistochemical staining, as
described in chapter 2.7.4, was performed to determine the dominating cell type in these
structures. For staining, primary antibodies against CD3 positive T-cells, B220 positive B-cells
as well as CD21 positive dendritic cells were used. In figure 19 it becomes obvious, that these
structures are highly positive for all stainings in old cigarette smoke exposed mice, which
strongly indicates that the structures in question indeed consist of lymphoid tissue. In young
mice, these structures are much rarer and not as intensely stained as in the old animals.
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Anti-CD3 antibody staining in young CS-exposed mice Anti-CD3 antibody staining in old CS-exposed mice
Anti-B220 antibody staining in young CS-exposed mice Anti-B220 antibody staining in old CS-exposed mice
Anti-CD21 antibody staining in young CS-exposed mice Anti-CD21 antibody staining in old CS-exposed mice
Figure 19: Immunohistochemical staining of iBALT structures with different antibodies, as described in chapter 2.7.4. As
iBALT structures could rarely be found in filter air exposed animals, the stainings are only presented from the lungs of
cigarette smoke exposed animals. It can be seen that iBALT structures are stained positive for T-cells (CD3), B-cells
(B220) as well as dendritic cells (CD21). These stainings are seen to be more intense in the older animals compared to
the younger group.
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3.3 Differentiation of T-cells
The analysis of BAL fluid shows an increase in different cell lines. The most prominent however
was the increase in T-cells (see chapter 2.4). Thus a more differentiated analysis of subtypes
seemed necessary. To accomplish this aim, we analysed CD4 positive T-helper cells taken from
whole lung tissue that was prepared and analysed as described in chapter 2.6.
These analyses show the greatest increase in the subgroup of Th17 T-helper cells (figure 20). A
strong increase of Th17 cells could be seen in the old CS-exposed mice compared to the filter
air exposed animals. No difference due to cigarette smoke exposure could be found between the
groups of young animals. Additionally a significant increase in the baseline levels of old filter
air exposed animals compared to the younger peers could be determined (see figure 20).
The analysis of Th2 cells shows similar findings. A significant increase was detected in old
compared to young CS-exposed animals. The slight increase in Th2 cells in old cigarette
smoke exposed animals compared to the filter air exposed peer group does not reach statistical
significance. Significant differences in base line levels were not found (see figure 21).
The analysis of Th1 cells showed no changes due to cigarette smoke exposure in both age groups.
However the analysis of baseline levels between the two age groups showed an increase in the
old FA exposed mice compared to younger peers (see figure 22).
The last subtype that was analysed were regulatory T-cells. In this analysis an increase in
numbers could only be shown for old CS-exposed mice. These differences however do not reach
statistical significance. No changes could be found for the young CS-exposed mice compared to
the filter air exposed group. Furthermore differences in baseline levels could not be detected
(see figure 23).
Figure 20: FACS Differentiation of Th17 CD4 positive T-
helper cells: An increase can be seen in the old cigarette
smoke exposed animals compared to both, the filter air ex-
posed peer group and the cigarette smoke exposed young
animals. Also a baseline increase in the old filter air ex-
posed animals is found.
Figure 21: FACS Differentiation of Th2 CD4 positive T-
helper cells: The analysis of Th2 cells shows a significant
increase in the old cigarette smoke exposed mice in com-
parison to the young cigarette smoke exposed animals.
Even though there is an increase also compared to the filter
air exposed old mice, it does not reach statistical signifi-
cance. No changes in baseline levels could be detected.
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Figure 22: FACS Differentiation of Th1 CD4 positive T-
helper cells: The only changes in the levels of Th1 are
seen in the baseline levels. A significant increase could
be found in the old filter air exposed animals compared to
the younger peer group. No changes in Th1 levels due to
smoking are seen.
Figure 23: FACS Differentiation of regulatory CD4 positive
T-helper cells: The analysis of regulatory T-cells only shows
an increase of regulatory T-cells for the old cigarette smoke
exposed animals. Due to small numbers this increase does
not reach statistical significance. There are no changes in
baseline levels.
3.4 Macrophage Markers
As already described in chapter 1.2.1, activated macrophages play an important role in the
development of COPD and emphysema.
3.4.1 MMP12-Matrix-Metallo-Proteinase 12
The most important marker for the activation status of macrophages is MMP12. To determine
the amount of activated macrophages, we performed an immunohistochemical staining, as
described in chapter 2.7.4 with the antibody given in table 13. We showed an increase in the
amount of MMP12 positive macrophages in the young as well as in the old cigarette smoke
exposed groups. This increase was greater in the older animals (see figure 26). To confirm
these findings we also performed a qPCR analysis to determine the amount of MMP12 RNA as
described in chapter 2.9 with the primers given in table 14. Figure 24 shows an increase in
MMP12 expression in both old and young animals after CS-exposure. This increase has been
shown to be significant in the old mice. The changes in case of the young animals do not reach
statistical significance. No baseline differences between the filter air exposed groups was found
(figure 24).
TIMP1 shows antagonistic effects to MMP12, so the effectiveness of MMP12 is also determined
by the amount of TIMP1. Thus, a quantification of TIMP1 was performed as well (for primers
see table 14), and the MMP12/TIMP1 ratio was determined. As no changes in TIMP1 could
be found in any of the groups, the MMP12/TIMP1 ratio mirrors the results we have already
seen in the analysis of MMP12 alone (figure 25).
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Figure 24: qPCR of MMP12 as described in chapter 2.9: An increase of MMP12 RNA was found in the old cigarette
smoke exposed animals compared to both, the filter air exposed peer group and the cigarette smoke exposed young
animals. The slight increase in younger mice due to cigarette smoke exposure does not reach statistical significance.
Figure 25: MMP12/TIMP1 ratio in lung tissue calculated from the results of qPCR as described in chapter 2.9: An
increase in the MMP12/TIMP1 ratio was found only in the old cigarette smoke exposed mice compared to both, the young
cigarette smoke exposed animals and the filter air exposed peer group.
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young filter air exposed mice
old filter air exposed mice
young CS exposed mice
old CS exposed mice
Figure 26: Lung tissue of the mice after immunohistochemical staining with MMP12 antibody (see table 13) as described
in chapter 2.7.4: An increase in MMP12 positive (red) macrophages can be seen in the old cigarette smoke exposed
animals compared to both the cigarette smoke exposed young animals as well as the filter air exposed peer group.
3.4.2 F4/80
Another important macrophage marker is F4/80, which is a surface protein of macrophages
[111]. In order to determine changes in its expression due to cigarette smoke, and thus the
number of macrophages, a qPCR on total lung homogenates was performed with the primers
given in table 14. This analysis resulted in a significant increase in F4/80 expression only for
the CS-exposed old animals, while there are no changes due to cigarette smoke exposure in
the young animals. One thus finds a significant difference between the old and young smoke
exposed animals. No differences in baseline values for the FA groups could be detected, thus
suggesting an increase in lung macrophages only after CS-exposure in older animals (figure
27).
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Figure 27: qPCR of F4/80 as described in chapter 2.9: An increase in the expression of F4/80 is seen in the old cigarette
smoke exposed mice both in comparison to the young cigarette smoke exposed animals and the filter air exposed peer
group. No changes due to cigarette smoke exposure could be detected in the young animals. There are no differences in
the baseline levels between the filter air exposed groups.
3.5 Chemoattractants
3.5.1 Monocyte chemoattractant protein 1
MCP-1 (CCL2) is a chemoattractant secreted predominantly by macrophages, although many
cell types can secrete it, to recruit monocytes to sites of inflammation, where they can mature
into macrophages [112]. Levels of MCP-1 mRNA in bronchiolar epithelial cells were shown
to correlate with the number of macrophages in airway epithelia [112]. As discussed before,
macrophages play an important role in the development of COPD (see chapters 1.2 and 3.4)
and therefore recruitment markers were determined in our experiment as well.
In the qPCR performed on whole lung tissue (as described in chapter 2.9 with the primers
in table 14) an increase in MCP-1 mRNA has been found in both smoking groups compared
to the reference groups. The increase seems somewhat higher in the old CS-exposed animals,
but there is no statistically significant difference between the two groups exposed to cigarette
smoke. No baseline differences bave been detected between old and young mice (figure 28).
3.5.2 CXCL1 (C-X-C motif ligand 1)
CXCL1 has been shown to be an essential factor for neutrophil recruitment. An increase in
neutrophils in the tissue of COPD patients has been demonstrated [59], even more so in COPD
patients that in addition show chronic bronchitis.
In the analysis of CXCL1 in whole lung tissue using qPCR (as described in chapter 2.9) a
significant increase of CXCL1 in the old CS-exposed animals, compared to filter air exposed
56
3.5 Chemoattractants
Figure 28: qPCR for MCP-1 in whole lung tissue as described in chapter 2.9: Increases in MCP-expression are seen in
both cigarette smoke exposed age groups compared to the filter air exposed peers. The differences between the old and
young cigarette smoke exposed groups are not significant. No differences in baseline levels are found.
control animals, has been detected. While the increase in the young CS-exposed animals is not
statistically significant, the difference between the increase in the old and young CS-exposed
mice is. Differences in base line levels could not be detected (figure 29).
3.5.3 CXCL-13 (C-X-C motif ligand 13)
CXCL13 is the most important B-cell chemoattractant and plays a key role in the development
of lymphoid follicles due to cigarette smoke exposure, as a lack of CXCL13 prevents lymphoid
follicles from forming and shows a protective effect in the development of COPD [113].
In the qPCR analysis of CXCL13 in whole lung tissue (as described in chapter 2.9) the only
significant change in expression levels was seen in the old CS-exposed mice compared to both
the filter air exposed old mice and young CS-exposed animals (figure 30). There were no
changes in baseline levels between old and young animals.
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Figure 29: qPCR for CXCL1 in whole lung tissue as described in chapter 2.9: Increases in CXCL1 expression levels
could be seen in the old cigarette smoke exposed animals compared to both, the filter air exposed peer group and the
cigarette smoke exposed young mice. Differences in baseline levels could not be detected.
Figure 30: qPCR for CXCL13 in whole lung tissue as described in chapter 2.9: Increases in CXCL13 levels have been
detected in the old cigarette smoke exposed animals compared to all peer groups. No differences in baseline levels could
be detected.
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3.6 Inflammation- and differentiation markers
To verify the results obtained in the analysis of iBALT and to further quantify inflammation,
the expressions of inflammation markers as well as transcription factors for T-cell differentiation
were determined.
In the analysis of interferon γ, no changes in RNA expression due to cigarette smoke could be
determined in either the old nor the young animals. Changes in the baseline levels between the
different age groups could not be seen (see figure 31).
As a Further inflammation marker that was investigated was Interleukin 13. In this analysis a
significant increase in the old CS-exposed mice could be detected. This increase was shown to
be significant both in comparison to the filter air exposed control group as well as to the young
CS-exposed mice. No changes could be determined in the young animals due to CS-exposure.
Differences in baseline levels between the two filter air exposed groups could not be found
(figure 32).
In addition, a determination of the expression of Gata3, a regulator for the differentiation of
Th2 cells was performed. Even though the number of Th2 cells increased due to cigarette smoke,
the expression of Gata3 slightly decreased in the cigarette smoke exposed animals compared to
the respective filter air exposed groups. These trends however are not statistically significant.
Differences in baseline levels of Gata3 in the filter air exposed groups could not be detected
(figure 33).
The next transcription factor that analysed was Rorγt, that promotes differentiation of T
cells into Th17 cells. Here we see results similar to the analysis of the amount of Th17 cells.
The analysis showed a significant increase of Rorγt in the old CS-exposed group compared
to the respective filter air group. This increase could also be shown in comparison to the
young CS-exposed animals. No changes could be seen in the young mice due to cigarette
smoke exposure. Differences in the baseline levels of both filter air exposed groups could not be
detected (see figure 34).
The last differentiation marker that was determined was Foxp3. Foxp3 is responsible for the
differentiation of T-cells into regulatory T-cells. In this analysis a slight increase in expression in
the old CS-exposed animals was visible, but the comparison with the filter air exposed animals
of the same age group showed no significance. No trends could be seen in any of the other
groups, neither between the young filter air exposed animals and the respective CS-exposed
groups, nor in the baseline levels of the young and old filter air exposed groups (figure 35).
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Figure 31: qPCR of Interferon-γ expression: No changes
due to cigarette smoke exposure or age could be de-
tected.
Figure 32: qPCR of IL13 expression: An increase in IL13
expression is seen in the old cigarette smoke exposed
group compared to all peer groups.
Figure 33: qPCR of Gata3 expression: Slight decreases
in Gata3 levels due to cigarette smoke were found, but did
not reach statistical significance. No changes in baseline
levels are seen.
Figure 34: qPCR of Rorγt expression: An increase in
Rorγt expression was found in the old cigarette smoke
exposed animals compared all peer groups.
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Figure 35: qPCR of Foxp3 expression: A slight increase in Foxp3 expression could be seen in the old cigarette smoke
exposed group, but it does not reach statistical significance. No changes in baseline levels could be detected.
3.7 BAL-Cell-Differentiation
Bronchioalveolar lavage was performed on the animals (as described in chapter 2.4) and slides
were prepared as discussed in chapter 2.7.1.
In the analysis of total cell counts, a significant increase in total cell count number between the
groups of young mice as well as for the cigarette smoke exposed mice has been found, both
for the young and old animals. Although both groups show a significant increase, there is still
a greater increase in total cell counts in the group of old CS-exposed mice in comparison to
young CS-exposed mice. No difference in base levels in the filter air exposed animals could be
detected (see figure 36).
To further distinguish between the different cells types, differential cell counts were performed,
as described in chapter 2.4. In differential cell counts, the same trends are seen in both
macrophages (see figure 37), which are the dominant cell type, as well as in neutrophils (see
figure 38). Also here no differences in base line levels could be detected. The cell line that
has been shown to be the most important one in the development of COPD is lymphocytes
(see chapter 1.2). In cell counts for lymphocytes, a significant increase has been found in the
old CS-exposed animals compared to the control group, while a slight increase in the young
cigarette smoke exposed mice compared to filter air exposed animals occurs with no statistical
significance (figure 39). The difference in the increase between old and young CS-exposed
animals is significant for the number of lymphocytes, while no baseline difference between the
filter air exposed animals can be seen.
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Figure 36: Total cell counts performed on BAL fluid: An
increase in total cell counts is seen in both cigarette smoke
exposed groups, with a larger increase in the old cigarette
smoke exposed group . No differences in baseline levels
are detected.
Figure 37: Total macrophage cell count in BAL fluid: An
increase in total macrophage count could be found in both
cigarette smoke exposed groups. The increase is larger for
the old cigarette smoke exposed animals. No differences
in baseline levels are found.
Figure 38: Total neutrophil cell count in BAL: The greatest
increase could be seen in the old cigarette smoke exposed
mice. An increase is also seen for the cigarette exposed
young animals. The number for the filter air exposed groups
is insignificant.
Figure 39: Total lymphocyte cell count in BAL: A signifi-
cant increase in total lymphocyte count is seen only in the
old cigarette smoke exposed animals. No differences in
baseline occured.
3.8 Ageing markers
3.8.1 p16
p16 has been described to play an important role in the development of tumours as well as to
increase with cellular senescence [114],[115]. In this context it can also be considered as a marker
of senescence. Therefore, an immunohistochemical staining for p 16 was performed (as described
in chapter 2.7.4) with the antibody given in table 13. The analysis of the corresponding slides
(see figure 40) suggested an increase in p16 due to cigarette smoke in both old and young
animals. In light of these findings further analysis was performed.
To determine the changes in p16 expression more accurately, a qPCR analysis was made (as
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described in chapter 2.9 with the p16 primers given in table 14).
The analysis shows an increase in the old smoke exposed mice compared to the filter air exposed
animals of the same age group. The analysis also exhibits a significant increase in the old
CS-exposed mice compared to the young smoke exposed animals. The latter on the other
hand do not show any changes compared to the respective filter air group. Also no changes in
baseline levels of p16 could be detected (see figure 41).
To further verify these results, additionally a western blot was done to not only investigate
mRNA expression, but also the protein expression of p16. Western blot was performed as
described in chapter 2.10, and a picture of the analysed membrane with markers and respective
β-actin expression are shown in in the attachment. Even though the changes are not found
to be significant in the analysis of the western blot, there was a slight increase in p16 in both
CS-exposed groups compared to filter air exposed animals.
young filter air exposed mice
old filter air exposed mice
young cigarette smoke exposed mice
old cigarette smoke exposed mice
Figure 40: Lung tissue of the mice after immunohistochemical staining with p16 antibody as described in chapter 2.7.4:
An increase in p16 positive cells (red)in the old cigarette smoke exposed animals compared to the other groups can be
seen.
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Figure 41: qPCR analysis of p16 in whole lung tissue as described in chapter 2.9: A significant increase is seen in the
old cigarette smoke exposed mice compared all peer groups. No differences in baseline levels could be detected.
Figure 42: Analysis of Western Blot of p16 in comparison to β-actin (see figure ??): Due to the small numbers of animals
analysed, the increases in the cigarette smoke exposed groups do not reach statistical significance
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3.8.2 p21
Another marker for cellular senescence is p21. To quantify changes in p21 expression due to
cigarette smoke, a qPCR analysis was performed as described in chapter 2.9 with the primers
listed in table 14.
The results of this analysis show (see figure 43) a slight decrease of p21 due to cigarette smoke
in both, the old and the young animals. These changes however are not statistically relevant.
Differences in baseline levels between the filter air exposed young and old animals could not be
detected.
Figure 43: qPCR analysis of p21 in whole lung tissue as described in chapter 2.9: A slight decrease in p21 levels are
visible for both cigarette smoke exposed groups, but did not reach statistical significance. The same goes for the decrease
in baseline levels for the old filter air exposed animals.
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3.8.3 SIRT1
SIRT1 is another important ageing marker. Thus an immunohistochemical staining of lung
tissue with an anti- SIRT1 antibody was performed. As visible in the resulting pictures (see
figure 44), the intensity of the red staining is decreased in the old animals, for both the filter air
and cigarette smoke exposed groups, when compared to younger peers. Additionally a decrease
due to cigarette smoke exposure is visible.
To further quantify the changes in SIRT1 expression, a qPCR of whole lung tissue was performed
as described in chapter 2.9 with the primers given in table 14.
The results show a significant decrease in both, the young and the old smoke exposed animals
compared to the respective filter air control groups. No differences in baseline levels was found.
While there is a decreasing trend visible in the old filter air exposed animals compared to young
animals, it does not reach statistical significance (see figure 45).
young filter air exposed mice
old filter air exposed mice
young cigarette smoke exposed mice
old cigarette smoke exposed mice
Figure 44: Lung tissue of the mice after immunohistochemical staining with SIRT1 antibody as described in chapter
2.7.4: A decrease in Sirt1 expression in the older animals can be seen. Additionally the SIRT1 expression seems to be
decreased in the cigarette smoke exposed groups.
To validate the PCR results, a western blot was additionally performed. Also in these results, a
significant decrease of SIRT1 in the young cigarette smoke exposed mice compared to the filter
air exposed animals has been detected. No differences can be seen in the old cigarette smoke
exposed group compared to old filter air exposed animals as the old filter air exposed animals
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Figure 45: qPCR analysis of SIRT1 in whole lung tissue as described in chapter 2.9: A significant decrease of SIRT1
due to cigarette smoke exposure can be seen in both, the old and the young animals. Additionally there seems to be a
slight decrease in baseline levels in the older filter air exposed animals, that does not reach statistical significance.
Figure 46: Analysis of Western Blot of SIRT1 in comparison to β-actin: A decrease in SIRT1 is seen in the young
animals due to cigarette smoke exposure. The decrease in baseline levels in old filter air exposed animals does not reach
statistical significance. This might be attributed to the low animal numbers that were tested.
have already reached the lowest expression levels of SIRT1. In accordance with those findings,
there was a decrease in baseline values of SIRT 1 in the old filter air exposed animals compared
to the young mice (figure 46).
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4 Discussion
4.1 The use of a mouse model to simulate COPD development
Epidemiologic studies have shown, that COPD is a disease that mainly occurs in old patients
(e.g. [7]). The aim of this thesis was to investigate if ageing itself plays an important role in
the development of COPD. In that case, the age distribution of COPD patients would not
only be a cumulative effect of cigarette smoke exposure. To discriminate the effect of smoke
from the influence of ageing, we exposed old and young mice to mainstream cigarette smoke.
This form of cigarette smoke exposure is the one that comes closest to mimic human smoking
habits. After three months of cigarette smoke exposure we noticed a decline in lung function,
defined by an increase in compliance, in the old animals, while there were no changes in the
young animals. In a stereological analysis of lung tissue we found however the development of
emphysema in both groups of aged mice, i.e. also for those only exposed to filter air only. This
finding is similar to senile emphysema described for humans: an age dependent decrease in lung
function as well as an enlargement in airspace have been observed for healthy elderly humans
compared to young controls. In contrast to emphysema development in COPD patients, senile
emphysema is characterized by airspace enlargement without destruction of the alveolar walls
[116]. However even though aged mice already show signs of emphysema development without
being exposed to cigarette smoke, the increase in airspace enlargement due to cigarette smoke
exposure is still significant. In addition to the development of emphysema, we have further
shown that in old animals the amount of collagen surrounding the airways increases due to
cigarette smoke exposure. The latter is similar to the findings in human COPD patients where
the total wall thickening as well as the thickening of each of the airway wall compartment show
a strong association with COPD progression as defined by the GOLD stages [1].
We should point out, that in contrast to our results Zhou et al. have reported [117] that after 6
months of cigarette smoke exposure old mice did not show enhanced emphysema compared
to young animals. These deviating results might be due to significant differences. Although
the same mouse strain and the same cigarettes have been used, the method of cigarette smoke
exposure was different. While in our experiments a smoke chamber for whole body exposure
with 20 cigarettes per day has been chosen, in [117] a nose only exposure with three cigarettes
per day was used. The latter might also account for the different cigarette smoke exposure
times required to develop emphysema. The long duration of the experiment required in [117] is
probably responsible for the missing age effect in this study. This hypothesis is supported by
a set of further experiments performed in our group. Here young mice exposed to cigarette
smoke for four months showed similar airspace enlargement as old mice did after three months
of cigarette smoke exposure [81]. Furthermore, unpublished data from our group show no
difference in airspace enlargement for old and young mice that were exposed to cigarette smoke
for four months. Thus, we conclude that the results in [117] are not in contradiction with our
findings of an age effect after three months of cigarette smoke exposure.
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4.2 The role of inflammation in the development of COPD
In the analysis of bronchioalveolar lavage fluid we have found an increase of total cell number
in both smoke exposed groups of mice. This effect has been much larger however for the old
animals. These findings are indicative of a more pronounced immune system activation in the
older mice. Since changes in the immune system due to ageing are well known, we performed an
analysis of the immune response of old animals compared to younger animals. We have found
an increase in inducible bronchus associated lymphoid tissue iBALT structures in old animals
exposed to cigarette smoke that could not be seen in any of the other groups. Such iBALT
structures are known to play an important role in the development of COPD. Hogg et al. [1]
have shown an association between the number of small airways containing lymphoid follicles
and the severity of the disease, defined by lung function analysis according to GOLD. These
findings could at least in part be attributed to an increase in collagen fibres in the subepthelium
of bronchioles occurring around these lymphoid structures [118].
Immunohistochemic staining of the iBALT structures in our experiment unveiled, that they
mainly consist of B-cells and T-cells as well as to a smaller amount, of dendritic cells. Both B-
and T-cells are well known to play a major role in the development of COPD [81].
Increased amounts of B-cells have been found in small airways of COPD patients [1] as well as
in biopsies of large airways of patients with COPD. It has further been shown, that increases
in the amount of B-cells in airways of COPD patients correlate with disease stage and lung
function (FEV1) [79]. In addition to the increase of B-cells in the airways of COPD patients,
infiltrates of B-cells were also found in lung interstitium. In a mouse model an increase in
both, size and number of such infiltrates could be proven to be caused by prolonged smoking
[80]. The importance of B-cells for both, the development of iBALT structures as well as for
emphysema could be demonstrated by cigarette smoke exposure of B-cell deficient mice [81]. In
these animals, an inability to form iBALT structures as well as an immunity to cigarette smoke
induced emphysema could be observed. This immunity to emphysema seems to be caused by
an inability of these animals to activate macrophages. In vitro experiments have shown that
B-cell derived IL10 is crucial for the activation of MMP12 expression in macrophages [81].
B-cells contained in iBALT stuctures produce CXCL13 which is a chemoattractant for other
B-cells. In the whole lung tissue derived from our experiments we have seen an increased
expression of CXCL13 for old cigarette smoke exposed mice only. This finding is consistent
with the increased numbers of iBALT structures observed in these mice. Increased amounts
of CXCL13 had already been described earlier, both in patients with COPD as well as in a
CS-mouse model for COPD [113], [119]. It was shown that CXCL13 is required for B-cell
migration into lung tissue and for the formation of iBALT. Since the B-cells contained in iBALT
structures also produce CXCL13, a positive feedback mechanism gets established. Treatment
with a CXCL13 antibody has prevented iBALT formation in prophylactic as well as therapeutic
approach [119].
iBALT structures also contain T-cells. There are different subtypes of T-cells contributing
to the development of COPD. It has been shown that cigarette smoke exposure can lead to
defective T-cells, that may give rise to emphysema development as well as to formation of
lymphoid follicles in immune deficient, but otherwise healthy animals, independent of cigarette
smoke exposure. This effect however has so far only be found in T-cells isolated from lung
tissue [71]. The effect of T-cells for emphysema development can also be caused by a changed
chemokine profile as it has been found that T-cells isolated from COPD patients have a changed
chemokine expression [120].
In the analysis of cells in bronchoalveolar lavage fluid we found an increase of total cell counts in
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both of the cigarette smoke exposed groups compared to the respective filter air exposed groups.
This increase was larger for the old smoke exposed mice than for the young ones. Further
differentiation of BAL cells unveiled an increase of lymphocytes in the old smoke exposed
animals only.
In our analysis of whole lung tissue, we found a significant increase in IL13 mRNA levels in
old cigarette smoke exposed animals when compared to both, the respective filter air exposed
group as well as the young cigarette smoke exposed group. The levels of IL13 in plasma of
COPD patients has been shown to correlate to lung function impairment [120].
To further investigate the T-cell response occurring in lungs due to long term cigarette smoke
exposure, the different subtypes of CD4 positive T-helper-cells in whole lung tissue were
differentiated. An increase in Th1 cells could be detected in old mice exposed to cigarette smoke
as well as in filter air exposed control animals. This leads to the assumption that the increase
in Th1 cells is age dependent. Th2 cells showed an increase in old cigarette smoke exposed
animals in comparison to young animals only, but no significant difference was found compared
to the filter air exposed control group. This finding is consistent with in vitro studies that
showed an increase in Th1 differentiation of human CD4+ cells after stimulation in comparison
to cells taken from younger subjects [121]. In our experiment the most prominent changes
regarding T-cells were found for the Th17 cells, that were significantly increased in the old
smoke exposed animals compared to all other control groups. These results are consistent with
previous findings, describing an increase in Th17 cells due to cigarette smoke [122]. Furthermore,
the number of IL17 producing T-helper cells has also been described to increase with age. The
up-regulation of Th17 cells is dependent on the retinoic acid related receptor γt (RORγt).
Pharmaceutical supression of RORγt showed a decreased differentiation of CD4+ T-helper cells
towards IL17 producing cells [122].
As we have already shown for the number of Th17 cells, RORγt mRNA expression in our
experiment has been found to be only increased in the old cigarette smoke exposed animals.
These findings are consistent with the results of Chu et al. [123] who have demonstrated a
significant increase of RORγt in COPD patients. In addition, it has been shown that the ratio
of Foxp3/RORγt is related to both, emphysema development as well as lung function analysis.
Corroborating these findings, the number of regulatory T-cells have been shown to decrease
with age. Regulatory T-cells are responsible for the down regulation of Th17 cells and therefore
have an anti-inflammatory effect [124]. They are thus important for regulating immune response
and inflammatory homoeostasis [125]. In our experiment there was a slight trend towards an
up-regulation of regulatory T-cells for the old cigarette smoke exposed mice which is consistent
with the findings of Schmitt et al. [124], who have demonstrated an increased up-regulation
of regulatory T-cells upon stimulation. We have seen the same trend as for regulatory T-cells
in the mRNA expression of Foxp3 in whole lung tissue where only a slight increase in old
smoke exposed animals is visible, but does not reach statistical significance. Foxp3 is a specific
transcription factor for regulatory T-cells and therefore is considered a reliable marker. [126]
The much greater increase in Th17 cells compared to regulatory T-cells would lead to an
increased expression of IL17. The role of IL17 has not yet been fully understood. It has been
shown however, that iBALT development is dependent on IL17, as IL17-deficient mice develop
only smaller and fewer iBALT structures after cigarette smoke exposure in comparison to wild
type animals. IL17 has been shown to be only required for the development, but not for the
maintenance of iBALT structures [127]. Since the development of iBALT structures also occurs
in COPD it can be assumed that the TH17 cells play an important role in COPD development.
In addition, it has been discovered that IL17 leads to an increased expression of matrix-metallo-
proteinases (MMP), in particular MMP12 as well as to a reduction of TIMP, an antagonist of
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MMPs. As MMP12 is secreted by macrophages, focal accumulation of mononuclear cells as well
as increased formation of lymphoid structures in mice over-expressing IL17 is to be expected
and has been shown. Since MMP12 has been unveiled to be one of the main contributors to
the development of emphysema, as expected mice unable to express IL17 show less emphysema
development than wild type animals after chronic exposure to cigarette smoke. In these animals,
also the total number of inflammatory cells in the lung after cigarette smoke exposure is
decreased in comparison to wild type animals [128], [129].
In addition to the increase in lymphocytes in bronchioalveolar lavage, we also found an increase
in macrophages. Even though the number of macrophages is increased in both cigarette exposed
groups, a significantly higher number has been detected in the old animals. Concomitant with
these results, an analysis of macrophage chemoattractant protein 1 (MCP1) in BAL has shown
an increase in both cigarette smoke exposed groups. MCP1 has been shown to be important
for COPD development. It has been found to be increased in sputum of COPD patients
and to correlate with FEV1 [130]. In addition, a correlation between MCP1 expression from
bronchial epithelial cells and the number of intraepithelial macrophages has been detected
[131]. Alveolar macrophages have been shown to be vital for the development of emphysema.
It has been demonstrated that mice deficient in matrixmetalloproteinases (MMP) are protected
against cigarette smoke induced emphysema [65]. Since these mice also recruit significantly
fewer macrophages to the alveoles, mice were instilled with MCP1 to stimulate the migration
of macrophages into the lungs [65]. These findings show that it is not the macrophages
themselves, but the MMPs they produce, that are responsible for the development of COPD.
Therefore an analysis of MMP12 expression of macrophages was performed in our experiment.
Immunohistochemic staining for MMP12 in lung tissue has shown more MMP12 positive
macrophages in old cigarette smoke exposed mice than in any of the other groups. To confirm
these findings, we performed a qPCR analysis of MMP12 mRNA expression in whole lung tissue.
We have found an increase of MMP12 expression in old cigarette exposed mice compared to
all other groups. Similar results could be seen in the analysis of the MMP12/TIMP1 ratio.
Since TIMP1 is an inhibitor of all MMPs, an increase in TIMP1 expression would inhibit the
development of emphysema [132]. Since no changes in TIMP1 expression could be detected, the
increase in MMP12/TIMP1 ratio can be solely attributed to the increase in MMP12. To confirm
these findings, another macrophage marker was analysed. F4/80 has been shown to be only
expressed by macrophages, and is therefore a reliable marker [111]. Furthermore, F4/80 has also
been found to be increased with maturation of macrophages [133]. In our experiment we have
seen an increase in F4/80 in cigarette exposed old mice only, confirming an increase in mature
alveolar macrophages. The last group of cells we investigated and that showed an increased
number in the analysis of bronchoalveolar lavage, are the neutrophils. The total neutrophil
count increased in both cigarette smoke exposed groups, but the increase was significantly
higher in the old cigarette smoke exposed mice when compared to young animals. To further
substantiate these findings, an analysis of mRNA expression of C-X-C motif ligand (CXCL1)
was performed. As with the total number of neutrophils, an increase could only be seen in the
old cigarette smoke exposed mice compared to the respective control groups as well as the young
cigarette smoke exposed animals. CXCL1 has been shown to be a powerful chemoattractant for
neutrophils. It has been demonstrated that chemotaxis of neutrophils is dependent on CXCL1
and CXCL2 [134]. Not only macrophages, but also neutrophils are important contributors
to the development of emphysema [135]. It has been shown that mice deficient in neutrophil
elastase have decreased airspace enlargement compared to wild type animals following cigarette
smoke exposure. In addition, neutrophil elastase proteolytically activates MMP12 and degrades
its inhibitor TIMP1 [135].
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Aging does not only occur in individuals, but can also be seen on the cellular level. An increase
in senescent cells in COPD patients compared to healthy non smoking as well as smoking
control subjects has been described. Cellular senescence has several markers of which the most
important ones that increase with age are p16 and p21. These markers have also been shown to
be negatively correlated to telomere length, which is a marker for replicative senescence. The
levels of cellular senescence markers have also been described to correlate with lung function
impairment [136]. The cell type with the greatest change in p16 expression in patients with
emphysema is type II alveolar cells [137]. Thus, in order to determine the changes in expression
of these senescence markers in our work, first an immunohistochemical staining for p16 was
performed. A slight increase in staining intensity could be seen in the old smoke exposed
mice. To further substantiate these findings we performed an analysis of mRNA expression of
p16. Here we determined a significant increase in expression levels only in old cigarette smoke
exposed mice compared to both the respective filter air group and the young cigarette smoke
exposed animals. Analysis of protein levels using western blot revealed no significant changes,
but this might be attributed to a difficult analysis of a small protein. For p21, no significant
changes could be detected. Chronic inflammation of the lung caused by cigarette smoke can
cause premature ageing of lung tissue. Premature senescence under these circumstances leads
to a decreased regenerative capacity that might contribute to emphysema development. It
has been demonstrated that tissue ageing due to chronic inflammation can be inhibited by
treatment with anti-inflammatory drugs [138].
Not only chronic inflammation is responsible for the premature ageing of the lung, but also the
cigarette smoke itself. It has been shown that cells treated with cigarette smoke extract show
signs of cellular senescence in combination with an irreversible growth arrest. Interestingly,
these changes have been found not to be caused by nicotine alone [139]. In addition to cellular
senescence caused by chronic inflammation, also replicative senescence due to an increased
destruction of cells might play a role. High turnover of cells results in shortening of telomeres,
which has been shown to cause increased emphysema development. In mice with shortened
telomeres, greater DNA damage due to cigarette smoke exposure has been found. In addition,
in mice with shortened telomeres, p21 fails to be down-regulated after smoking cessation, which
might account in part for the continuous decline in lung function of COPD patients after
smoking cessation. Mutations in telomerase genes have been found to be a risk factor for both,
the development of COPD as well as pulmonary fibrosis [140].
The other important ageing marker that plays a role in COPD development is SIRT1. SIRT1
has been shown to decrease in mice exposed to cigarette smoke [141]. Similar results have also
been shown for human smokers and COPD patients [142]. We have shown a decrease in SIRT1
in both cigarette smoke exposed groups, but have seen no changes between the old and the
young animals. A decrease in SIRT1 has been found to predispose for emphysema development
upon cigarette smoke exposure. In addition, overexpression of SIRT1 has been demonstrated to
have a protective effect against the development of emphysema, making it a prime target for
pharmaceutical approaches [141]. SIRT1 has been found to decrease autophagy which explains
why decreased levels of SIRT1 attribute to the development of COPD [143].
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5 Conclusion and Outlook
In conclusion, we have found that aged mice develop cigarette smoke induced emphysema at
an earlier time-point of cigarette smoke exposure than younger animals do. The development
of emphysema was substantiated by lung function analysis as well as stereological analysis of
embedded lung tissue where we found an increased mean alveolar intercept. Since changes in
lung function are usually attributed to small airway disease, we analysed the remodelling of
small airways. Here we found an increase in airway collagen. One of the main theories for
COPD development is that COPD might be caused by an immune response to cigarette smoke.
We have shown an increased amount of bronchus associated lymphoid tissue (iBALT) as well as
an increase in inflammatory cells in the broncholaveolar lavage. The greatest changes were to
be seen in the numbers of Th17 CD4 positive T-helper cells, the number and activation status
(defined by the expression of MMP12) of macrophages and the number of neutrophils. All of
these cell lines were increased in the lungs of old cigarette smoke exposed mice, but neither,
or at least not as much, in the lungs of old filter air exposed controls nor in young cigarette
smoke exposed animals. Changes in the immune response due to ageing have been decribed in
humans as well as in mice. Thus, to determine whether the changes in the immune response we
have seen in the old animals are due to cellular senescence, an analysis of ageing markers on
lung tissue was performed. We have seen an increase in the ageing marker p16 in old smoke
exposed mice, indicating an increased cellular senescence. In addition, a decrease in SIRT1 in
both cigarette smoke exposed groups could be found.
For further investigations, the smoking experiment could be repeated using young mice that
received a bone marrow transplant with aged cells. This could substantiate our hypothesis that
an aged immune system predisposes for the development of cigarette smoke induced COPD.
Another possibility would be to expose even older mice to cigarette smoke, as 12 month old
mice would correlate to middle aged humans, that still rarely develop emphysema.
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